LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors; Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors; Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD; Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia; Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia; Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH); Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.
## CONTENTS

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
020702Orig1s060

APPROVAL LETTER
Dear Ms. Douglas:

Please refer to your Supplemental New Drug Application (sNDA) dated September 30, 2011, received September 30, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LIPITOR (atorvastatin calcium) Tablets 10 mg, 20 mg, 40 mg, and 80 mg.

We acknowledge receipt of your amendments dated December 2, 2011, and January 12, February 7 and 24, 2012.

We also refer to our letter dated August 11, 2011, requesting that sponsors of HMG-CoA reductase inhibitor (statin) drugs, modify their labeling based on our comprehensive review of clinical trial data, Adverse Event Reporting System (AERS) reports, the published literature, and the labels of other approved drugs containing information on statin coadministration.

This “Prior Approval” supplemental new drug application provides for revisions to the WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS sections of the Highlights of Prescribing Information section and changes to the DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DRUG INTERACTIONS, CLINICAL PHARMACOLOGY and PATIENT COUNSELING INFORMATION sections of the Full Prescribing Information sections of the LIPITOR (atorvastatin) package insert, and corresponding revisions to the LIPITOR (atorvastatin) patient package insert.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at
Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 796-1295.

Sincerely,

{See appended electronic signature page}

Amy G. Egan, M.D., M.P.H.
Deputy Director for Safety
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMY G EGAN
02/28/2012

Reference ID: 3093302
APPLICATION NUMBER:
020702Orig1s060

LABELING
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR.

LIPITOR® (atorvastatin calcium) Tablets for oral administration
Initial U.S. Approval: 1996

RECENT MAJOR CHANGES

Drug Interactions (7) 02/2012

INDICATIONS AND USAGE

LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
•  Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors (1.1).
•  Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors (1.1).
•  Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD (1.1).
•  Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (1.2).
•  Reduce elevated TG in patients with hypertriglyceridemia and primary dysbeta lipoproteinemia (1.2).
•  Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) (1.2).
•  Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy (1.2).

Limitations of Use
LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias.

DOSE AND ADMINISTRATION

Dose range: 10 to 80 mg once daily (2.1).
Recommended start dose: 10 or 20 mg once daily (2.1). Patients requiring large LDL-C reduction (>45%) may start at 40 mg once daily (2.1).
Pediatric starting dose: 10 mg once daily; maximum recommended dose: 20 mg once daily (2.2).

DOSE FORMS AND STRENGTHS

10, 20, 40, and 80 mg tablets (3).

CONTRAINDICATIONS

Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4.1).
Women who are pregnant or may become pregnant (4.3).
Nursing mothers (4.4).
Hypersensitivity to any component of this medication (4.2).

WARNINGS AND PRECAUTIONS

Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment. Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. In cases of myopathy or rhabdomyolysis, therapy should be temporarily withheld or discontinued (5.1, 8.5).
Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (5.2).

A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs. placebo (5.5).

ADVERSE REACTIONS

The most commonly reported adverse reactions (incidence ≥ 2%) in patients treated with LIPITOR in placebo-controlled trials regardless of causality were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and www.pfizer.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)</td>
<td>Avoid atorvastatin</td>
</tr>
<tr>
<td>HIV protease inhibitor (lopinavir plus ritonavir)</td>
<td>Use with caution and lowest dose necessary</td>
</tr>
<tr>
<td>Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td>Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr>
<td>HIV protease inhibitor (nelfinavir)</td>
<td>Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>

Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with LIPITOR (7).
Digoxin: Patients should be monitored appropriately (7.8).
Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased (7.9).
Rifampin should be simultaneously co-administered with LIPITOR (7.7).

USE IN SPECIFIC POPULATIONS

Hepatic impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease (12.3).

See 17 for PATIENT COUNSELING INFORMATION

Revised: [02/2012]

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
   1.1 Prevention of Cardiovascular Disease
   1.2 Hyperlipidemia
   1.3 Limitations of Use
2 DOSAGE AND ADMINISTRATION
   2.1 Hyperlipidemia
   2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients
   2.3 Homozygous Familial Hypercholesterolemia
   2.4 Concomitant Lipid-Lowering Therapy
   2.5 Dosage in Patients With Renal Impairment
   2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
   4.1 Active Liver Disease which may include Unexplained Persistent Elevation of
Hepatic Transaminase Levels
4.2 Hypersensitivity to any Component of this Medication
4.3 Pregnancy
4.4 Nursing Mothers

5 WARNINGS AND PRECAUTIONS
5.1 Skeletal Muscle
5.2 Liver Dysfunction
5.3 Endocrine Function
5.4 CNS Toxicity
5.5 Use in Patients with Recent Stroke or TIA

6 ADVERSE REACTIONS
6.1 Clinical Trial Adverse Experiences
6.2 Postintroduction Reports
6.3 Pediatric Patients (ages 10-17 years)

7 DRUG INTERACTIONS
7.1 Strong Inhibitors of Cytochrome P450 3A4:
   Clarithromycin
   Combination of Protease Inhibitors
   Itraconazole
7.2 Grapefruit Juice
7.3 Cyclosporine
7.4 Gemfibrozil
7.5 Other Fibrates
7.6 Niacin
7.7 Rifampin or other Inducers of Cytochrome P450 3A4
7.8 Digoxin
7.9 Oral Contraceptives
7.10 Warfarin
7.11 Colchicine

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
14.1 Prevention of Cardiovascular Disease
14.2 Hyperlipidemia and Mixed Dyslipidemia
14.3 Hypertriglyceridemia
14.4 Dysbetalipoproteinemia
14.5 Homozygous Familial Hypercholesterolemia
14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION
17.1 Muscle Pain
17.2 Liver Enzymes
17.3 Pregnancy
17.4 Breastfeeding

*Sections or subsections omitted from the full prescribing information are not listed.
1 INDICATIONS AND USAGE
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet.

1.1 Prevention of Cardiovascular Disease
In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, LIPITOR is indicated to:
- Reduce the risk of myocardial infarction
- Reduce the risk of stroke
- Reduce the risk for revascularization procedures and angina

In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to:
- Reduce the risk of myocardial infarction
- Reduce the risk of stroke

In patients with clinically evident coronary heart disease, LIPITOR is indicated to:
- Reduce the risk of non-fatal myocardial infarction
- Reduce the risk of fatal and non-fatal stroke
- Reduce the risk for revascularization procedures
- Reduce the risk of hospitalization for CHF
- Reduce the risk of angina

1.2 Hyperlipidemia
LIPITOR is indicated:
- As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
- As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
- For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
- To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
- As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with homozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
  a. LDL-C remains ≥ 190 mg/dL or
  b. LDL-C remains ≥ 160 mg/dL and:
     - there is a positive family history of premature cardiovascular disease or
     - two or more other CVD risk factors are present in the pediatric patient

1.3 Limitations of Use
LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).
2 DOSAGE AND ADMINISTRATION

2.1 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The recommended starting dose of LIPITOR is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of LIPITOR is 10 to 80 mg once daily. LIPITOR can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of LIPITOR should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP Guidelines). After initiation and/or upon titration of LIPITOR, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)

The recommended starting dose of LIPITOR is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current NCEP Pediatric Panel Guidelines, Clinical Pharmacology (12), and Indications and Usage (1.2)]. Adjustments should be made at intervals of 4 weeks or more.

2.3 Homozygous Familial Hypercholesterolemia

The dosage of LIPITOR in patients with homozygous FH is 10 to 80 mg daily. LIPITOR should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

2.4 Concomitant Lipid-Lowering Therapy

LIPITOR may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].

2.5 Dosage in Patients With Renal Impairment

Renal disease does not affect the plasma concentrations nor LDL-C reduction of LIPITOR; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions, Skeletal Muscle (5.1), Clinical Pharmacology, Pharmacokinetics (12.3)].

2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors

In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with LIPITOR should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with LIPITOR should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed. In patients with HIV taking nelfinavir, therapy with LIPITOR should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].

3 DOSAGE FORMS AND STRENGTHS

White, elliptical, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin calcium.

4 CONTRAINDICATIONS

4.1 Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels

4.2 Hypersensitivity to any component of this medication

4.3 Pregnancy

Women who are pregnant or may become pregnant. LIPITOR may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of LIPITOR use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. LIPITOR SHOULD BE
ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)].

4.4 Nursing mothers

It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPITOR treatment should not breastfeed their infants [see Use in Specific Populations (8.3)].

5 WARNINGS AND PRECAUTIONS

5.1 Skeletal Muscle

Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.

Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.

Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.

The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see Drug Interactions (7)). Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.

Prescribing recommendations for interacting agents are summarized in Table 1 [see also Dosage and Administration (2.6), Drug Interactions (7), Clinical Pharmacology (12.3)].

| Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis |
|-----------------------------------------------|-----------------------------------------------|
| Interacting Agents                           | Prescribing Recommendations                   |
| Cyclosporine, HIV protease inhibitors         | Avoid atorvastatin                            |
| inhibitors (tipranavir plus ritonavir)        |                                               |
| hepatitis C protease inhibitor (telaprevir)   |                                               |
| HIV protease inhibitor (lopinavir plus ritonavir) | Use with caution and lowest dose necessary |
| Clarithromycin, itraconazole, HIV protease inhibitors | Do not exceed 20 mg atorvastatin daily |
| (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) |                                               |
| HIV protease inhibitor (nelfinavir)           | Do not exceed 40 mg atorvastatin daily         |

*Use with caution and with the lowest dose necessary (12.3)
Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see Drug Interactions (7.11)].

LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).

5.2 Liver Dysfunction

Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (>3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.

One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequela. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of LIPITOR.

It is recommended that liver enzyme tests be obtained prior to initiating therapy with LIPITOR and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with LIPITOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart LIPITOR.

LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see Contraindications (4.1)].

5.3 Endocrine Function

Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.

Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that LIPITOR does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.

5.4 CNS Toxicity

Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day.

CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallarian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.

5.5 Use in Patients with Recent Stroke or TIA

In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic
and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see Adverse Reactions (6.1)].

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the label:
Rhabdomyolysis and myopathy [see Warnings and Precautions (5.1)]
Liver enzyme abnormalities [see Warnings and Precautions (5.2)]

6.1 Clinical Trial Adverse Experiences

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).

The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%).

Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials.

| Table 2. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients). |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Adverse Reaction* | Any dose N=8755 | 10 mg N=3908 | 20 mg N=188 | 40 mg N=604 | 80 mg N=4055 | Placebo N=7311 |
| Nasopharyngitis | 8.3 | 12.9 | 5.3 | 7.0 | 4.2 | 8.2 |
| Arthralgia | 6.9 | 8.9 | 11.7 | 10.6 | 4.3 | 6.5 |
| Diarrhea | 6.8 | 7.3 | 6.4 | 14.1 | 5.2 | 6.3 |
| Pain in extremity | 6.0 | 8.5 | 3.7 | 9.3 | 3.1 | 5.9 |
| Urinary tract infection | 5.7 | 6.9 | 6.4 | 8.0 | 4.1 | 5.6 |
| Dyspepsia | 4.7 | 5.9 | 3.2 | 6.0 | 3.3 | 4.3 |
| Nausea | 4.0 | 3.7 | 3.7 | 7.1 | 3.8 | 3.5 |
| Musculoskeletal pain | 3.8 | 5.2 | 3.2 | 5.1 | 2.3 | 3.6 |
| Muscle Spasms | 3.6 | 4.6 | 4.8 | 5.1 | 2.4 | 3.0 |
| Myalgia | 3.5 | 3.6 | 5.9 | 8.4 | 2.7 | 3.1 |
| Insomnia | 3.0 | 2.8 | 1.1 | 5.3 | 2.8 | 2.9 |
| Pharyngolaryngeal pain | 2.3 | 3.9 | 1.6 | 2.8 | 0.7 | 2.1 |

* Adverse Reaction ≥ 2% in any dose greater than placebo

Other adverse reactions reported in placebo-controlled studies include:
Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; Musculoskeletal system: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and nutritional system: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; Nervous system: nightmare; Respiratory system: epistaxis; Skin and appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive.

Reference ID: 3093302
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
In ASCOT [see Clinical Studies (14.1)] involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.

Collaborative Atorvastatin Diabetes Study (CARDS)
In CARDS [see Clinical Studies (14.1)] involving 2,838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with LIPITOR 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.

Treatting to New Targets Study (TNT)
In TNT [see Clinical Studies (14.1)] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 x ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).

Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)
In IDEAL [see Clinical Studies (14.1)] involving 8,888 subjects (age range 26–80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥3 x ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (≥10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see Warnings and Precautions (5.5)].

In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 LIPITOR vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) LIPITOR vs. 2 (4%) placebo].

There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, and pancreatitis.

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious,
and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

6.3 Pediatric Patients (ages 10-17 years)

In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily was generally similar to that of placebo [see Clinical Studies (14.6) and Use in Special Populations, Pediatric Use (8.4)].

7 DRUG INTERACTIONS

The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)].

7.1 Strong Inhibitors of CYP 3A4: LIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4.

Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].

Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of LIPITOR should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of LIPITOR should not exceed 20 mg and should be used with caution [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].

Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].

7.2 Grapefruit Juice: Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).

7.3 Cyclosporine: Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. The co-administration of LIPITOR with cyclosporine should be avoided [see Warnings and Precautions, Skeletal Muscle (5.1)].

7.4 Gemfibrozil: Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of LIPITOR with gemfibrozil should be avoided [see Warnings and Precautions, Skeletal Muscle (5.1)].

7.5 Other Fibrates: Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIPITOR should be administered with caution when used concomitantly with other fibrates [see Warnings and Precautions (5.1)].

7.6 Niacin: The risk of skeletal muscle effects may be enhanced when LIPITOR is used in combination with niacin; a reduction in LIPITOR dosage should be considered in this setting [see Warnings and Precautions (5.1)].

7.7 Rifampin or other Inducers of Cytochrome P450 3A4: Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
7.8 **Digoxin:** When multiple doses of LIPITOR and digoxin were co-administered, steady state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored appropriately.

7.9 **Oral Contraceptives:** Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.

7.10 **Warfarin:** LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.

7.11 **Colchicine:** Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.

8 **USE IN SPECIFIC POPULATIONS**

8.1 **Pregnancy**

Pregnancy Category X

LIPITOR is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid lowering drugs offer no benefit during pregnancy because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy.

There are no adequate and well-controlled studies of atorvastatin use during pregnancy. There have been rare reports of congenital anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified.

Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m²) [see Contraindications, Pregnancy (4.3)].

In a study in rats given 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, neonate, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at 80 mg/day.

Statins may cause fetal harm when administered to a pregnant woman. LIPITOR should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes pregnant while taking LIPITOR, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus and the lack of known clinical benefit with continued use during pregnancy.

8.3 **Nursing Mothers**

It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother’s milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women requiring LIPITOR treatment should be advised not to nurse their infants [see Contraindications (4)].

8.4 **Pediatric Use**

Safety and effectiveness in patients 10-17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial of 6 months’ duration in adolescent boys and postmenarchal girls. Patients treated with LIPITOR had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were infections. **Doses greater than 20 mg have not been studied in this patient population.** In this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual
cycle length in girls [see Clinical Studies (14.6); Adverse Reactions, Pediatric Patients (ages 10-17 years) (6.3); and Dosage and Administration, Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age) (2.2)]. Adolescent females should be counseled on appropriate contraceptive methods while on LIPITOR therapy [see Contraindications, Pregnancy (4.3) and Use in Specific Populations, Pregnancy (8.1)]. LIPITOR has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.

Clinical efficacy with doses up to 80 mg/day for 1 year have been evaluated in an uncontrolled study of patients with homozygous FH including 8 pediatric patients [see Clinical Studies, Homozygous Familial Hypercholesterolemia (14.5)].

8.5 Geriatric Use

Of the 39,828 patients who received LIPITOR in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for myopathy, LIPITOR should be prescribed with caution in the elderly.

8.6 Hepatic Impairment

Lipitor is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see Contraindications (4) and Pharmacokinetics (12.3)].

10 OVERDOSAGE

There is no specific treatment for LIPITOR overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance LIPITOR clearance.

11 DESCRIPTION

LIPITOR is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.

Atorvastatin calcium is [R-(R*, R*)]-2-(4-fluorophenyl)-ß, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate. The empirical formula of atorvastatin calcium is (C₃₃H₃₄FN₂O₅)₂Ca•3H₂O and its molecular weight is 1209.42. Its structural formula is:

![Structural formula of atorvastatin calcium](image)

Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol.

LIPITOR Tablets for oral administration contain 10, 20, 40, or 80 mg atorvastatin and the following inactive ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Reference ID: 3093302
LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles. LIPITOR reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication(s).

A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B (a membrane complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C.


Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.

12.2 Pharmacodynamics

LIPITOR, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see Dosage and Administration (2)].

12.3 Pharmacokinetics

Absorption: LIPITOR is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to LIPITOR dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether LIPITOR is given with or without food. Plasma LIPITOR concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see Dosage and Administration (2)].

Distribution: Mean volume of distribution of LIPITOR is approximately 381 liters. LIPITOR is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, LIPITOR is likely to be secreted in human milk [see Contraindications, Nursing Mothers (4.4) and Use in Specific Populations, Nursing Mothers (8.3)].

Metabolism: LIPITOR is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of LIPITOR. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of LIPITOR in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.1)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.
Excretion: LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of LIPITOR is recovered in urine following oral administration.

Specific Populations

Geriatric: Plasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see Use in Specific Populations, Geriatric Use (8.5)].

Pediatric: Pharmacokinetic data in the pediatric population are not available.

Gender: Plasma concentrations of LIPITOR in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with LIPITOR between men and women.

Renal Impairment: Renal disease has no influence on the plasma concentrations or LDL-C reduction of LIPITOR; thus, dose adjustment in patients with renal dysfunction is not necessary [see Dosage and Administration, Dosage in Patients with Renal Impairment (2.5), Warnings and Precautions, Skeletal Muscle (5.1)].

Hemodialysis: While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins.

Hepatic Impairment: In patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Contraindications (4.1)].

<table>
<thead>
<tr>
<th>Co-administered drug and dosing regimen</th>
<th>Atorvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose (mg)</td>
</tr>
<tr>
<td>#Cyclosporine 5.2 mg/kg/day, stable dose</td>
<td>10 mg QD for 28 days</td>
</tr>
<tr>
<td>#Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td>10 mg, SD</td>
</tr>
<tr>
<td>#Telaprevir 750 mg q8h, 10 days</td>
<td>20 mg, SD</td>
</tr>
<tr>
<td>#Telaprevir 750 mg q8h, 10 days</td>
<td>20 mg, SD</td>
</tr>
<tr>
<td>#Squinnavir 400 mg BID/ritonavir 400mg BID, 15 days</td>
<td>40 mg QD for 4 days</td>
</tr>
<tr>
<td>#Clarithromycin 500 mg BID, 9 days</td>
<td>80 mg QD for 8 days</td>
</tr>
<tr>
<td>#Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>#Itraconazole 200 mg QD, 4 days</td>
<td>40 mg SD</td>
</tr>
<tr>
<td>#Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>#Fosamprenavir 1400 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>#Nelfinavir 1250 mg BID, 14 days</td>
<td>10 mg QD for 28 days</td>
</tr>
<tr>
<td>#Grapefruit Juice, 240 mL QD</td>
<td>40 mg, SD</td>
</tr>
<tr>
<td>Diltiazem 240 mg QD, 28 days</td>
<td>40 mg, SD</td>
</tr>
<tr>
<td>Erythromycin 500 mg QID, 7 days</td>
<td>10 mg, SD</td>
</tr>
<tr>
<td>Amlodipine 10 mg, single dose</td>
<td>80 mg, SD</td>
</tr>
<tr>
<td>Cimetidine 300 mg QD, 4 weeks</td>
<td>10 mg QD for 2 weeks</td>
</tr>
<tr>
<td>Colestipol 10 mg BID, 28 weeks</td>
<td>40 mg QD for 28 weeks</td>
</tr>
<tr>
<td>Maalox TC® 30 mL QD, 17 days</td>
<td>10 mg QD for 15 days</td>
</tr>
<tr>
<td>Efavirenz 600 mg QD, 14 days</td>
<td>10 mg for 3 days</td>
</tr>
<tr>
<td>#Rifampin 600 mg QD, 7 days (co-administered) †</td>
<td>40 mg SD</td>
</tr>
<tr>
<td>#Rifampin 600 mg QD, 5 days (doses separated) ‡</td>
<td>40 mg SD</td>
</tr>
<tr>
<td>#Gemfibrozil 600mg BID, 7 days</td>
<td>40mg SD</td>
</tr>
</tbody>
</table>

Reference ID: 3093302
<table>
<thead>
<tr>
<th>Atorvastatin</th>
<th>Co-administered drug and dosing regimen</th>
<th>Change in AUC</th>
<th>Change in Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>80 mg QD for 15 days</td>
<td>Antipyrine, 600 mg SD</td>
<td>↑ 3%</td>
<td>↓ 11%</td>
</tr>
<tr>
<td>80 mg QD for 14 days</td>
<td># Digoxin 0.25 mg QD, 20 days</td>
<td>↑ 15%</td>
<td>↑ 20%</td>
</tr>
<tr>
<td>40 mg QD for 22 days</td>
<td>Oral contraceptive QD, 2 months - norethindrone 1mg - ethinyl estradiol 35μg</td>
<td>↑ 28%</td>
<td>↑ 23%</td>
</tr>
<tr>
<td>10 mg, SD</td>
<td>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>10 mg QD for 4 days</td>
<td>Fosamprenavir 1400 mg BID, 14 days</td>
<td>↓ 27%</td>
<td>↓ 18%</td>
</tr>
<tr>
<td>10 mg QD for 4 days</td>
<td>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td>No change</td>
<td>No change</td>
</tr>
</tbody>
</table>

* See Section 7 for clinical significance.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose.

A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in high-dose females. These findings occurred at plasma AUC (0–24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.

In vitro, atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation: the Ames test with Salmonella typhimurium and Escherichia coli, the HGPRT forward mutation assay in Chinese hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the in vivo mouse micronucleus test.

Studies in rats performed at doses up to 175 mg/kg (15 times the human exposure) produced no changes in fertility. There was aplasia and aspermina in the epididymis of 2 of 10 rats treated with 100 mg/kg/day of atorvastatin for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg and epididymal weight was lower at 100 mg/kg. Male rats given 100 mg/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of 10, 40, or 120 mg/kg for two years.

Reference ID: 3093302
14 CLINICAL STUDIES

14.1 Prevention of Cardiovascular Disease

In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of LIPITOR on fatal and non-fatal coronary heart disease was assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), without a previous myocardial infarction and with TC levels ≤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age >55 years (84.5%), smoking (33.2%), diabetes (24.3%), history of CHD in a first-degree relative (26%), TC:HDL >6 (14.3%), peripheral vascular disease (5.1%), left ventricular hypertrophy (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), proteinuria/albuminuria (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-hypertensive therapy (Goal BP <140/90 mm Hg for non-diabetic patients; <130/80 mm Hg for diabetic patients) and allocated to either LIPITOR 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.

The effect of 10 mg/day of LIPITOR on lipid levels was similar to that seen in previous clinical trials.

LIPITOR significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the placebo group vs. 40 events in the LIPITOR group) or non-fatal MI (108 events in the placebo group vs. 60 events in the LIPITOR group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for LIPITOR vs. 3.0% for placebo), p=0.0005 (see Figure 1)]. The risk reduction was consistent regardless of age, smoking status, obesity, or presence of renal dysfunction. The effect of LIPITOR was seen regardless of baseline LDL levels. Due to the small number of events, results for women were inconclusive.

Figure 1: Effect of LIPITOR 10 mg/day on Cumulative Incidence of Non-Fatal Myocardial Infarction or Coronary Heart Disease Death (in ASCOT-LLA)

LIPITOR also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for LIPITOR and 2.3% for placebo). There was no significant difference between the treatment groups for death due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).

In the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of LIPITOR on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40–75 with type 2 diabetes based on WHO criteria, without prior history of cardiovascular disease and with LDL ≤160 mg/dL and TG ≤600 mg/dL. In addition to diabetes, subjects had 1 or more of the following risk factors: current smoking (23%), hypertension (80%), retinopathy (30%), or microalbuminuria (9%) or macroalbuminuria (3%). No subjects on hemodialysis were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either LIPITOR 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke. The primary analysis was the time to first occurrence of the primary endpoint.

Reference ID: 3093302
Baseline characteristics of subjects were: mean age of 62 years, mean HbA1c 7.7%; median LDL-C 120 mg/dL; median TC 207 mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL.

The effect of LIPITOR 10 mg/day on lipid levels was similar to that seen in previous clinical trials.

LIPITOR significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the LIPITOR group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see Figure 2). An effect of LIPITOR was seen regardless of age, sex, or baseline lipid levels.

LIPITOR significantly reduced the risk of stroke by 48% (21 events in the LIPITOR group vs. 39 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the LIPITOR group vs. 64 events in the placebo group), HR 0.58, 95% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD death.

There were 61 deaths in the LIPITOR group vs. 82 deaths in the placebo group (HR 0.73, p=0.059).

Figure 2: Effect of LIPITOR 10 mg/day on Time to Occurrence of Major Cardiovascular Event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS

In the Treating to New Targets Study (TNT), the effect of LIPITOR 80 mg/day vs. LIPITOR 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level <130 mg/dL after completing an 8-week, open-label, run-in period with LIPITOR 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of LIPITOR and followed for a median duration of 4.9 years. The primary endpoint was the time-to-first occurrence of any of the following major cardiovascular events (MCVE): death due to CHD, non-fatal myocardial infarction, resuscitated cardiac arrest, and fatal and non-fatal stroke. The mean LDL-C, TC, TG, non-HDL, and HDL cholesterol levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of LIPITOR and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of LIPITOR.

Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002 (see Figure 3 and Table 5). The overall risk reduction was consistent regardless of age (<65, ≥65) or gender.

Figure 3: Effect of LIPITOR 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)
<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Atorvastatin 10 mg (N=5006)</th>
<th>Atorvastatin 80 mg (N=4995)</th>
<th>HR* (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRIMARY ENDPOINT</td>
<td>n (%)</td>
<td>n (%)</td>
<td>0.78 (0.69, 0.89)</td>
</tr>
<tr>
<td>First major cardiovascular endpoint</td>
<td>548 (10.9)</td>
<td>434 (8.7)</td>
<td>0.80 (0.61, 1.03)</td>
</tr>
<tr>
<td>Components of the Primary Endpoint</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD death</td>
<td>127 (2.5)</td>
<td>101 (2.0)</td>
<td>0.78 (0.66, 0.93)</td>
</tr>
<tr>
<td>Non-fatal, non-procedure related MI</td>
<td>308 (6.2)</td>
<td>243 (4.9)</td>
<td>0.78 (0.66, 0.93)</td>
</tr>
<tr>
<td>Resuscitated cardiac arrest</td>
<td>26 (0.5)</td>
<td>25 (0.5)</td>
<td>0.96 (0.56, 1.67)</td>
</tr>
<tr>
<td>Stroke (fetal and non-fatal)</td>
<td>155 (3.1)</td>
<td>117 (2.3)</td>
<td>0.75 (0.59, 0.96)</td>
</tr>
<tr>
<td>SECONDARY ENDPOINTS*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First CHF with hospitalization</td>
<td>164 (3.3)</td>
<td>122 (2.4)</td>
<td>0.74 (0.59, 0.94)</td>
</tr>
<tr>
<td>First PVD endpoint</td>
<td>282 (5.6)</td>
<td>275 (5.5)</td>
<td>0.97 (0.83, 1.15)</td>
</tr>
<tr>
<td>First CABG or other coronary revascularization procedureb</td>
<td>904 (18.1)</td>
<td>667 (13.4)</td>
<td>0.72 (0.65, 0.80)</td>
</tr>
<tr>
<td>First documented angina endpointc</td>
<td>615 (12.3)</td>
<td>545 (10.9)</td>
<td>0.88 (0.79, 0.99)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>282 (5.6)</td>
<td>284 (5.7)</td>
<td>1.01 (0.85, 1.19)</td>
</tr>
<tr>
<td>Components of All-Cause Mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>155 (3.1)</td>
<td>126 (2.5)</td>
<td>0.81 (0.64, 1.03)</td>
</tr>
<tr>
<td>Noncardiovascular death</td>
<td>127 (2.5)</td>
<td>158 (3.2)</td>
<td>1.25 (0.99, 1.57)</td>
</tr>
<tr>
<td>Cancer death</td>
<td>75 (1.5)</td>
<td>85 (1.7)</td>
<td>1.13 (0.83, 1.55)</td>
</tr>
<tr>
<td>Other non-CV death</td>
<td>43 (0.9)</td>
<td>58 (1.2)</td>
<td>1.35 (0.91, 2.00)</td>
</tr>
<tr>
<td>Suicide, homicide, and other traumatic non-CV death</td>
<td>9 (0.2)</td>
<td>15 (0.3)</td>
<td>1.67 (0.73, 3.82)</td>
</tr>
</tbody>
</table>

a Atorvastatin 80 mg: atorvastatin 10 mg  
b Component of other secondary endpoints  
* Secondary endpoints not included in primary endpoint  
HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=myocardial infarction; CHF=congestive heart failure;  
CV=cardiovascular; PVD=peripheral vascular disease; CABG=coronary artery bypass graft  
Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons

Of the events that comprised the primary efficacy endpoint, treatment with LIPITOR 80 mg/day significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal stroke, but not CHD death or resuscitated cardiac arrest (Table 5). Of the predefined secondary endpoints, treatment with LIPITOR 80 mg/day significantly reduced the rate of coronary revascularization, angina, and hospitalization for heart failure, but not peripheral vascular disease. The reduction in the rate of CHF with hospitalization was only observed in the 8% of patients with a prior history of CHF.

There was no significant difference between the treatment groups for all-cause mortality (Table 5). The proportions of subjects who experienced cardiovascular death, including the components of CHD death and fatal stroke, were numerically smaller in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group. The proportions of subjects who experienced noncardiovascular death were numerically larger in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group.

In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with LIPITOR 80 mg/day was compared to treatment with simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL, and non-HDL cholesterol levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of LIPITOR and 105, 179, 142, 47, and 132 mg/dL during treatment with 20–40 mg of simvastatin.

There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, non-fatal MI, and resuscitated cardiac arrest): 411 (9.3%) in the LIPITOR 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI (0.78, 1.01), p=0.07.

Reference ID: 3093302
There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the LIPITOR 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV death were similar for the LIPITOR 80 mg group and the simvastatin 20–40 mg group.

14.2 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (*Fredrickson Types IIa and IIb*)

LIPITOR reduces total-C, LDL-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with hyperlipidemia and mixed dyslipidemia. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.

LIPITOR is effective in a wide variety of patient populations with hyperlipidemia, with and without hypertriglyceridemia, in men and women, and in the elderly.

In two multicenter, placebo-controlled, dose-response studies in patients with hyperlipidemia, LIPITOR given as a single dose over 6 weeks, significantly reduced total-C, LDL-C, apo B, and TG. (Pooled results are provided in Table 6.)

**TABLE 6. Dose Response in Patients With Primary Hyperlipidemia (Adjusted Mean % Change From Baseline)**

<table>
<thead>
<tr>
<th>Dose</th>
<th>N</th>
<th>TC</th>
<th>LDL-C</th>
<th>Apo B</th>
<th>TG</th>
<th>HDL-C</th>
<th>Non-HDL-C/ HDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>21</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>-3</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>22</td>
<td>-29</td>
<td>-39</td>
<td>-32</td>
<td>-19</td>
<td>6</td>
<td>-34</td>
</tr>
<tr>
<td>20</td>
<td>20</td>
<td>-33</td>
<td>-43</td>
<td>-35</td>
<td>-26</td>
<td>9</td>
<td>-41</td>
</tr>
<tr>
<td>40</td>
<td>21</td>
<td>-37</td>
<td>-50</td>
<td>-42</td>
<td>-29</td>
<td>6</td>
<td>-45</td>
</tr>
<tr>
<td>80</td>
<td>23</td>
<td>-45</td>
<td>-60</td>
<td>-50</td>
<td>-37</td>
<td>5</td>
<td>-53</td>
</tr>
</tbody>
</table>

* Results are pooled from 2 dose-response studies.

In patients with *Fredrickson* Types IIa and IIb hyperlipoproteinemia pooled from 24 controlled trials, the median (25th and 75th percentile) percent changes from baseline in HDL-C for LIPITOR 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.

In three multicenter, double-blind studies in patients with hyperlipidemia, LIPITOR was compared to other statins. After randomization, patients were treated for 16 weeks with either LIPITOR 10 mg per day or a fixed dose of the comparative agent (Table 7).
### TABLE 7. Mean Percentage Change From Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)

<table>
<thead>
<tr>
<th>Treatment (Daily Dose)</th>
<th>N</th>
<th>Total-C</th>
<th>LDL-C</th>
<th>Apo B</th>
<th>TG</th>
<th>HDL-C</th>
<th>Non-HDL-C/ HDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study 1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>707</td>
<td>-27a</td>
<td>-36a</td>
<td>-28a</td>
<td>-17a</td>
<td>+7</td>
<td>-37a</td>
</tr>
<tr>
<td>Lovastatin 20 mg</td>
<td>191</td>
<td>-19</td>
<td>-27</td>
<td>-20</td>
<td>-6</td>
<td>+7</td>
<td>-28</td>
</tr>
<tr>
<td>95% CI for Diff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-9.2, -6.5</td>
<td>-10.7, -7.1</td>
<td>20.0, -5.5</td>
<td>-10.0, -6.5</td>
<td>-15.2, -7.1</td>
<td>1.7, 2.0</td>
<td>-11.1, -7.1</td>
</tr>
<tr>
<td><strong>Study 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>222</td>
<td>-25b</td>
<td>-35b</td>
<td>-27b</td>
<td>-17b</td>
<td>+6</td>
<td>-36b</td>
</tr>
<tr>
<td>Pravastatin 20 mg</td>
<td>77</td>
<td>-17</td>
<td>-23</td>
<td>-17</td>
<td>-9</td>
<td>+8</td>
<td>-28</td>
</tr>
<tr>
<td>95% CI for Diff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-10.8, -6.1</td>
<td>-14.5, -8.2</td>
<td>-13.4, -7.4</td>
<td>-14.1, -0.7</td>
<td>-4.9, 1.6</td>
<td>-11.5, -4.1</td>
<td></td>
</tr>
<tr>
<td><strong>Study 3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>132</td>
<td>-29c</td>
<td>-37c</td>
<td>-34c</td>
<td>-23c</td>
<td>+7</td>
<td>-39c</td>
</tr>
<tr>
<td>Simvastatin 10 mg</td>
<td>45</td>
<td>-24</td>
<td>-30</td>
<td>-30</td>
<td>-15</td>
<td>+7</td>
<td>-33</td>
</tr>
<tr>
<td>95% CI for Diff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-8.7, -2.7</td>
<td>-10.1, -2.6</td>
<td>-8.0, -1.1</td>
<td>-15.1, -0.7</td>
<td>-4.3, 3.9</td>
<td>-9.6, -1.9</td>
<td></td>
</tr>
</tbody>
</table>

1 A negative value for the 95% CI for the difference between treatments favors LIPITOR for all except HDL-C, for which a positive value favors LIPITOR. If the range does not include 0, this indicates a statistically significant difference.

a Significantly different from lovastatin, ANCOVA, p ≤ 0.05

b Significantly different from pravastatin, ANCOVA, p ≤ 0.05

c Significantly different from simvastatin, ANCOVA, p ≤ 0.05

The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 7 is not known. Table 7 does not contain data comparing the effects of LIPITOR 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable.

### 14.3 Hypertriglyceridemia (Fredrickson Type IV)

The response to LIPITOR in 64 patients with isolated hypertriglyceridemia treated across several clinical trials is shown in the table below (Table 8). For the LIPITOR-treated patients, median (min, max) baseline TG level was 565 (267–1502).

### TABLE 8. Combined Patients With Isolated Elevated TG: Median (min, max) Percentage Change From Baseline

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=12)</th>
<th>LIPITOR 10 mg (N=37)</th>
<th>LIPITOR 20 mg (N=13)</th>
<th>LIPITOR 80 mg (N=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides</td>
<td>-12.4 (-36.6, 82.7)</td>
<td>-41.0 (-76.2, 49.4)</td>
<td>-38.7 (-62.7, 29.5)</td>
<td>-51.8 (-82.8, 41.3)</td>
</tr>
<tr>
<td>Total-C</td>
<td>-2.3 (-15.5, 24.4)</td>
<td>-28.2 (-44.9, -6.8)</td>
<td>-34.9 (-49.6, -15.2)</td>
<td>-44.4 (-63.5, -3.8)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>3.6 (-31.3, 31.6)</td>
<td>-26.5 (-57.7, 9.8)</td>
<td>-30.4 (-53.9, 0.3)</td>
<td>-40.5 (-60.6, -13.8)</td>
</tr>
<tr>
<td>HDL-C</td>
<td>3.8 (-18.6, 13.4)</td>
<td>13.8 (-9.7, 61.5)</td>
<td>11.0 (-3.2, 25.2)</td>
<td>7.5 (-10.8, 37.2)</td>
</tr>
<tr>
<td>VLDL-C</td>
<td>-1.0 (-31.9, 53.2)</td>
<td>-48.8 (-85.8, 57.3)</td>
<td>-44.6 (-62.2, -10.8)</td>
<td>-62.0 (-88.2, 37.6)</td>
</tr>
<tr>
<td>non-HDL-C</td>
<td>-2.8 (-17.6, 30.0)</td>
<td>-33.0 (-52.1, -13.3)</td>
<td>-42.7 (-53.7, -17.4)</td>
<td>-51.5 (-72.9, -4.3)</td>
</tr>
</tbody>
</table>

### 14.4 Dysbetalipoproteinemia (Fredrickson Type III)

The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia (Fredrickson Type III) are shown in the table below (Table 9).

### TABLE 9. Open-Label Crossover Study of 16 Patients With Dysbetalipoproteinemia (Fredrickson Type III)

<table>
<thead>
<tr>
<th></th>
<th>Median (min, max) at Baseline (mg/dL)</th>
<th>Median % Change (min, max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total-C</td>
<td>442 (225, 1320)</td>
<td>-37 (-85, 17) -58 (-90, -31)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>678 (273, 5990)</td>
<td>-39 (-92, -8) -53 (-95, -30)</td>
</tr>
<tr>
<td>IDL-C + VLDL-C</td>
<td>215 (111, 613)</td>
<td>-32 (-76, 9) -63 (-90, -8)</td>
</tr>
<tr>
<td>non-HDL-C</td>
<td>411 (218, 1272)</td>
<td>-43 (-87, -19) -64 (-92, -36)</td>
</tr>
</tbody>
</table>
14.5 Homozygous Familial Hypercholesterolemia

In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of LIPITOR. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.

14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients

In a double-blind, placebo-controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolemia (FH) or severe hypercholesterolemia, were randomized to LIPITOR (n=140) or placebo (n=47) for 26 weeks and then all received LIPITOR for 26 weeks. Inclusion in the study required 1) a baseline LDL-C level ≥ 190 mg/dL or 2) a baseline LDL-C level ≥ 160 mg/dL and positive family history of FH or documented premature cardiovascular disease in a first or second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 138.5–385.0 mg/dL) in the LIPITOR group compared to 230.0 mg/dL (range: 160.0–324.5 mg/dL) in the placebo group. The dosage of LIPITOR (once daily) was 10 mg for the first 4 weeks and up titrated to 20 mg if the LDL-C level was > 130 mg/dL. The number of LIPITOR-treated patients who required up titration to 20 mg after Week 4 during the double-blind phase was 80 (57.1%).

LIPITOR significantly decreased plasma levels of total-C, LDL-C, triglycerides, and apolipoprotein B during the 26-week double-blind phase (see Table 10).

<table>
<thead>
<tr>
<th>DOSAGE</th>
<th>N</th>
<th>Total-C</th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>TG</th>
<th>Apolipoprotein B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>47</td>
<td>-1.5</td>
<td>-0.4</td>
<td>-1.9</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>LIPITOR</td>
<td>140</td>
<td>-31.4</td>
<td>-39.6</td>
<td>2.8</td>
<td>-12.0</td>
<td>-34.0</td>
</tr>
</tbody>
</table>

The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in the LIPITOR group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the placebo group during the 26-week double-blind phase.

The safety and efficacy of doses above 20 mg have not been studied in controlled trials in children. The long-term efficacy of LIPITOR therapy in childhood to reduce morbidity and mortality in adulthood has not been established.

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

10 mg tablets: coded “PD 155” on one side and “10” on the other.
NDC 0071-0155-23 bottles of 90
NDC 0071-0155-34 bottles of 5000
NDC 0071-0155-40 10 x 10 unit dose blisters

20 mg tablets: coded “PD 156” on one side and “20” on the other.
NDC 0071-0156-23 bottles of 90
NDC 0071-0156-40 10 x 10 unit dose blisters
NDC 0071-0156-94 bottles of 5000

40 mg tablets: coded “PD 157” on one side and “40” on the other.
NDC 0071-0157-23 bottles of 90
NDC 0071-0157-73 bottles of 500
NDC 0071-0157-88 bottles of 2500
NDC 0071-0157-40 10 x 10 unit dose blisters
80 mg tablets: coded “PD 158” on one side and “80” on the other.
NDC 0071-0158-23 bottles of 90
NDC 0071-0158-73 bottles of 500
NDC 0071-0158-88 bottles of 2500
NDC 0071-0158-92 8 x 8 unit dose blisters

Storage
Store at controlled room temperature 20 - 25°C (68 - 77°F) [see USP].

17 PATIENT COUNSELING INFORMATION

Patients taking LIPICTOR should be advised that cholesterol is a chronic condition and they should adhere to their medication along with their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program as appropriate, and periodic testing of a fasting lipid panel to determine goal attainment.

Patients should be advised about substances they should not take concomitantly with atorvastatin [see Warnings and Precautions (5.1)]. Patients should also be advised to inform other healthcare professionals prescribing a new medication that they are taking LIPICTOR.

17.1 Muscle Pain
All patients starting therapy with LIPICTOR should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness, or weakness. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (>1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.

17.2 Liver Enzymes
It is recommended that liver enzyme tests be performed before the initiation of LIPICTOR and if signs or symptoms of liver injury occur. All patients treated with LIPICTOR should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.

17.3 Pregnancy
Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using LIPICTOR. Discuss future pregnancy plans with your patients, and discuss when to stop LIPICTOR if they are trying to conceive. Patients should be advised that if they become pregnant, they should stop taking LIPICTOR and call their healthcare professional.

17.4 Breastfeeding
Women who are breastfeeding should be advised to not use LIPICTOR. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professional.

Distributed by
Parke-Davis
Division of Pfizer Inc, NY, NY 18017

LAB-0021-27.0

Reference ID: 3093302
PATIENT INFORMATION

LIPITOR
atorvastatin calcium
(LIP-ih-tore))

Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

If you have any questions about LIPITOR, ask your doctor or pharmacist.

What is LIPITOR?
LIPITOR is a prescription medicine that lowers cholesterol in your blood. It lowers the LDL-C ("bad" cholesterol) and triglycerides in your blood. It can raise your HDL-C ("good" cholesterol) as well. LIPITOR is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone.

LIPITOR can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as:
- age, smoking, high blood pressure, low HDL-C, heart disease in the family.

LIPITOR can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as:
- eye problems, kidney problems, smoking, or high blood pressure.

LIPITOR starts to work in about 2 weeks.

Who Should Not Take LIPITOR?
Do not take LIPITOR if you:
- are pregnant or think you may be pregnant, or are planning to become pregnant. Liptor may harm your unborn baby. If you get pregnant, stop taking LIPITOR and call your doctor right away.
- are breast feeding. LIPITOR can pass into your breast milk and may harm your baby.
- have liver problems.
- are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.

LIPITOR has not been studied in children under 10 years of age.

Before You Start LIPITOR
Tell your doctor if you:
- have muscle aches or weakness
- drink more than 2 glasses of alcohol daily
- have diabetes
- have a thyroid problem
- have kidney problems

Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:
- your immune system
- cholesterol
- infections
- birth control
- heart failure
- HIV or AIDS

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

What Should I Avoid While Taking LIPITOR?
- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?
LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:

How Should I Take LIPITOR?
- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
- Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.
- Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.
- If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.

- If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?
LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:

How Should I Take LIPITOR?
- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
- Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.
- Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.
- If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.

- If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

What Should I Avoid While Taking LIPITOR?
- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?
LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:

How Should I Take LIPITOR?
- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.
- Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.
- Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.
- If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.

- If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

What Should I Avoid While Taking LIPITOR?
- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.
- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?
LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:
• **Muscle problems.** LIPITOR can cause serious muscle problems that can lead to kidney problems, including kidney failure. You have a higher chance for muscle problems if you are taking certain other medicines with LIPITOR.

• **Liver problems.** Your doctor should do blood tests to check your liver before you start taking LIPITOR and if you have symptoms of liver problems while you take LIPITOR. Call your doctor right away if you have the following symptoms of liver problems:
  - feel tired or weak
  - loss of appetite
  - upper belly pain
  - dark amber colored urine
  - yellowing of your skin or the whites of your eyes

Call your doctor right away if you have:

- muscle problems like weakness, tenderness, or pain that happen without a good reason, especially if you also have a fever or feel more tired than usual.
- allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away.
- nausea and vomiting.
- passing brown or dark-colored urine.
- you feel more tired than usual
- your skin and whites of your eyes get yellow.
- stomach pain.
- allergic skin reactions.

In clinical studies, patients reported the following common side effects while taking LIPITOR: diarrhea, upset stomach, muscle and joint pain, and alterations in some laboratory blood tests.

The following additional side effects have been reported with LIPITOR:

- tiredness, tendon problems, memory loss, and confusion.
- allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away.
- nausea and vomiting.
- passing brown or dark-colored urine.
- you feel more tired than usual
- your skin and whites of your eyes get yellow.
- stomach pain.
- allergic skin reactions.

Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.

These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.

How do I store LIPITOR

- Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).
- Do not keep medicine that is out of date or that you no longer need.
- Keep LIPITOR and all medicines out of the reach of children. Be sure that if you throw medicine away, it is out of the reach of children.

**General Information About LIPITOR**

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at www.lipitor.com.

**What are the Ingredients in LIPITOR?**

**Active Ingredient:** atorvastatin calcium

**Inactive Ingredients:** calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS–1–7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.
APPLICATION NUMBER:
020702Orig1s060

Tracked Changes Label
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LIPTOR safely and effectively. See full prescribing information for LIPTOR.

LIPTOR® (atorvastatin calcium) Tablets for oral administration
Initial U.S. Approval: 1996

--- RECENT MAJOR CHANGES ---
02/2012

INDICATIONS AND USAGE
LIPTOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
- Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors (1.1).
- Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors (1.1).
- Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD (1.1).
- Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (1.2).
- Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia (1.2).
- Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) (1.2).
- Reduce elevated total-C, LDL-C, and apo B levels in boys and prepubertal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy (1.2).

Limitations of Use
LIPTOR has not been studied in Fredrickson Types I and V dyslipidemias.

DOSE AND ADMINISTRATION
Dose range: 10 to 80 mg once daily (2.1).
Recommended start dose: 10 or 20 mg once daily (2.1).
Patients requiring large LDL-C reduction (>45%) may start at 40 mg once daily (2.2).
Pediatric starting dose: 10 mg once daily, maximum recommended dose: 20 mg once daily (2.2).

DOSE FORMS AND STRENGTHS
10, 20, 40, and 80 mg tablets (3).

CONTRAINDICATIONS
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4.1).
Women who are pregnant or may become pregnant (4.3).
Nursing mothers (4.4).
Hypersensitivity to any component of this medication (4.2).

WARNINGS AND PRECAUTIONS
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine, fenofibrate, and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (>65), uncontrolled hypocholesterolemia, and renal impairment. Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. In cases of myopathy or rhabdomyolysis, therapy should be temporarily withheld or discontinued (5.1, 5.5).
Liver enzyme abnormalities and monitoring. Persistent elevations in hepatic transaminases can occur. Monitor liver enzymes before initiating therapy and during treatment clinically indicated thereafter (5.2).
A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPTOR 80 mg group vs. placebo (5.5).

ADVERSE REACTIONS
The most commonly reported adverse reactions (incidence ≥3%) in patients treated with LIPTOR in placebo-controlled trials regardless of causality were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 and www.pfizer.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)

Interacting Agents | Prescribing Recommendations
---|---
Cyclosporine, HIV protease inhibitors (indinavir or ritonavir), hepatitis C protease inhibitor (telaprevir) | Do not exceed 10 mg atorvastatin daily Avoid atorvastatin
HIV protease inhibitor (lopinavir plus ritonavir) | Do not exceed 10 mg atorvastatin daily Use with caution and lowest dose necessary
Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir or lopinavir or ritonavir) darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir | Caution when exceeding doses >20 mg atorvastatin daily The lowest dose necessary should be used Do not exceed 20 mg atorvastatin daily
HIV protease inhibitors (atazanavir plus ritonavir) | Do not exceed 40 mg atorvastatin daily

Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with LIPTOR (7).
Diabetes: Patients should be monitored appropriately (7.67-7.78).
Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased (7.67-7.82).
Rifampin should be simultaneously co-administered with LIPTOR (7.67-7.7).

USE IN SPECIFIC POPULATIONS
Hepatic Impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease (12.3).
See 17 for PATIENT COUNSELING INFORMATION
Revised: [12/201102/2012]

FULL PRESCRIBING INFORMATION: CONTENTS

1 INDICATIONS AND USAGE
1.1 Prevention of Cardiovascular Disease
1.2 Hyperlipidemia
1.3 Limitations of Use
2 DOSAGE AND ADMINISTRATION
2.1 Hyperlipidemia
2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients
2.3 Homozygous Familial Hypercholesterolemia
2.4 Concomitant Lipid-Lowering Therapy
2.5 Dosage in Patients With Renal Impairment
2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors

Combination of Ritonavir plus Saquinavir or Lopinavir plus Ritonavir

Reference ID: 3093302
3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS
4.1 Active Liver Disease which may include Unexplained Persistent Elevations of Hepatic Transaminase Levels
4.2 Hypersensitivity to any Component of this Medication
4.3 Pregnancy
4.4 Nursing Mothers

5 WARNINGS AND PRECAUTIONS
5.1 Skeletal Muscle
5.2 Liver Dysfunction
5.3 Endocrine Function
5.4 CNS Toxicity
5.5 Use in Patients with Recent Stroke or TIA

6 ADVERSE REACTIONS
6.1 Clinical Trial Adverse Experiences
6.2 Postintroduction Reports
6.3 Pediatric Patients (ages 10-17 years)

7 DRUG INTERACTIONS
7.1 Strong Inhibitors of Cytochrome P450 3A4:

7.2 Grapefruit Juice
7.3 Cyclosporine
7.4 Gemfibrozil
7.5 Other Fibrates
7.6 Niacin
7.7 Rifampin or other Inducers of Cytochrome P450 3A4
7.8 Digoxin
7.9 Oral Contraceptives
7.10 Warfarin
7.11 Colchicine

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
14.1 Prevention of Cardiovascular Disease
14.2 Hyperlipidemia and Mixed Dyslipidemia
14.3 Hypertriglyceridemia
14.4 Dysbetalipoproteinemia
14.5 Homozygous Familial Hypercholesterolemia
14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
1 INDICATIONS AND USAGE
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet.

1.1 Prevention of Cardiovascular Disease
In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, LIPITOR is indicated to:
• Reduce the risk of myocardial infarction
• Reduce the risk of stroke
• Reduce the risk for revascularization procedures and angina

In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to:
• Reduce the risk of myocardial infarction
• Reduce the risk of stroke

In patients with clinically evident coronary heart disease, LIPITOR is indicated to:
• Reduce the risk of non-fatal myocardial infarction
• Reduce the risk of fatal and non-fatal stroke
• Reduce the risk for revascularization procedures
• Reduce the risk of hospitalization for CHF
• Reduce the risk of angina

1.2 Hyperlipidemia
LIPITOR is indicated:
• As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
• As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
• For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
• To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
• As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with homozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
  a. LDL-C remains ≥ 190 mg/dL or
  b. LDL-C remains ≥ 160 mg/dL and:
    • there is a positive family history of premature cardiovascular disease or
    • two or more other CVD risk factors are present in the pediatric patient

1.3 Limitations of Use
LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).

Reference ID: 3093302
2 DOSAGE AND ADMINISTRATION

2.1 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The recommended starting dose of LIPITOR is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of LIPITOR is 10 to 80 mg once daily. LIPITOR can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of LIPITOR should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP Guidelines). After initiation and/or upon titration of LIPITOR, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)

The recommended starting dose of LIPITOR is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current NCEP Pediatric Panel Guidelines, Clinical Pharmacology (12), and Indications and Usage (1.2)]. Adjustments should be made at intervals of 4 weeks or more.

2.3 Homozygous Familial Hypercholesterolemia

The dosage of LIPITOR in patients with homozygous FH is 10 to 80 mg daily. LIPITOR should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

2.4 Concomitant Lipid-Lowering Therapy

LIPITOR may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].

2.5 Dosage in Patients With Renal Impairment

Renal disease does not affect the plasma concentrations nor LDL-C reduction of LIPITOR; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions, Skeletal Muscle (5.1), Clinical Pharmacology, Pharmacokinetics (12.3)].

2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors a Combination of Ritonavir plus Saquinavir or Lopinavir plus Ritonavir

In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy should be limited to with LIPITOR 40 mg once daily should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of ritonavir plus saquinavir, or lopinavir plus ritonavir, or fosamprenavir plus ritonavir, or fosamprenavir plus ritonavir, for doses of therapy with LIPITOR should be limited to exceeding 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed. In patients with HIV taking nelfinavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with LIPITOR should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed [see Warnings and Precautions, Skeletal Muscle (5.1), Drug Interactions (7)].

3 DOSAGE FORMS AND STRENGTHS

White, elliptical, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin calcium.

4 CONTRAINDICATIONS

4.1 Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels

4.2 Hypersensitivity to any component of this medication

4.3 Pregnancy

Women who are pregnant or may become pregnant. LIPITOR may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of
LIPITOR use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. LIPITOR SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1)].

4.4 Nursing mothers

It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPITOR treatment should not breastfeed their infants [see Use in Specific Populations (8.3)].

5 WARNINGS AND PRECAUTIONS

5.1 Skeletal Muscle

Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.

Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.

Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.

The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including ritonavir plus saquinavir, plus ritonavir, or lopinavir plus ritonavir, or tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, plus saquinavir or lopinavir plus ritonavir, darunavir plus ritonavir, or fosamprenavir or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see Drug Interactions (7)). Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.

Prescribing recommendations for interacting agents are summarized in Table 1 [see also Dosage and Administration (2.6), Drug Interactions (7), Clinical Pharmacology (12.3)].
Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)</td>
<td>Do not exceed 10 mg atorvastatin daily Avoid atorvastatin</td>
</tr>
<tr>
<td>HIV protease inhibitor (lopinavir plus ritonavir)</td>
<td>Do not exceed 10 mg atorvastatin daily Use with caution and lowest dose necessary</td>
</tr>
<tr>
<td>Clarithromycin, itraconazole, HIV protease inhibitors (ritonavir plus saquinavir plus ritonavir*, or lopinavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td>Caution when exceeding doses &gt; 20 mg atorvastatin daily. The lowest dose necessary should be used. Do not exceed 20 mg atorvastatin daily</td>
</tr>
<tr>
<td>HIV protease inhibitors (nelfinavir), fosamprenavir, fosamprenavir plus ritonavir)</td>
<td>Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>

*Use with caution and with the lowest dose necessary (12,3)

Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see Drug Interactions (7.8, 107, 111)].

LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).

5.2 Liver Dysfunction

Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (>3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.

One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of LIPITOR.

It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Liver enzyme changes generally occur in the first 3 months of treatment with LIPITOR. Patients who develop increased transaminase levels should be monitored until the abnormalities resolve. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended.

It is recommended that liver enzyme tests be obtained prior to initiating therapy with LIPITOR and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with LIPITOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart LIPITOR.

LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see Contraindications (4.1)].

5.3 Endocrine Function

Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.

Reference ID: 3093302
Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that LIPITOR does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.

5.4 CNS Toxicity

Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day.

CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.

5.5 Use in Patients with Recent Stroke or TIA

In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see Adverse Reactions (6.1)].

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the label:

Rhabdomyolysis and myopathy [see Warnings and Precautions (5.1)]
Liver enzyme abnormalities [see Warnings and Precautions (5.2)]

6.1 Clinical Trial Adverse Experiences

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).

The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%).

Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials.

<table>
<thead>
<tr>
<th>Table 2. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference ID: 3093302</td>
</tr>
<tr>
<td>Adverse Reaction*</td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
</tr>
<tr>
<td>Arthralgia</td>
</tr>
<tr>
<td>Diarrhea</td>
</tr>
<tr>
<td>Pain in extremity</td>
</tr>
<tr>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>Dyspepsia</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
</tr>
<tr>
<td>Muscle Spasms</td>
</tr>
<tr>
<td>Myalgia</td>
</tr>
<tr>
<td>Insomnia</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
</tr>
</tbody>
</table>

* Adverse Reaction ≥ 2% in any dose greater than placebo

Other adverse reactions reported in placebo-controlled studies include:

**Body as a whole:** malaise, pyrexia; **Digestive system:** abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; **Musculoskeletal system:** musculoskeletal pain, muscle fatigue, neck pain, joint swelling; **Metabolic and nutritional system:** transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; **Nervous system:** nightmare; **Respiratory system:** epistaxis; **Skin and appendages:** urticaria; **Special senses:** vision blurred, tinnitus; **Urogenital system:** white blood cells urine positive.

**Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)**
In ASCOT [see Clinical Studies (14.1)] involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.

**Collaborative Atorvastatin Diabetes Study (CARDS)**
In CARDS [see Clinical Studies (14.1)] involving 2,838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with LIPITOR 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.

**Treating to New Targets Study (TNT)**
In TNT [see Clinical Studies (14.1)] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥ 3 x ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).

**Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)**
In IDEAL [see Clinical Studies (14.1)] involving 8,888 subjects (age range 26–80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.

**Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)**
In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations

Reference ID: 3093302
of CK (>10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see Warnings and Precautions (5.5)].

In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 LIPITOR vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) LIPITOR vs. 2 (4%) placebo].

There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, memory impairment, depression, and peripheral neuropathy, and pancreatitis.

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

6.3 Pediatric Patients (ages 10-17 years)

In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily was generally similar to that of placebo [see Clinical Studies (14.6) and Use in Special Populations, Pediatric Use (8.4)].

7 DRUG INTERACTIONS

The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)].

7.1 Strong Inhibitors of CYP 3A4: LIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4.

**Clarithromycin:** Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].

**Combination of Protease Inhibitors:** Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, ritonavir plus saquinavir (100 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitors tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of LIPITOR should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, the dose of LIPITOR should not exceed 10 mg caution should be used when prescribing LIPITOR and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, or darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of LIPITOR should not exceed 20 mg and should be used with caution. caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].
Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].

7.2 Grapefruit Juice: Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).

7.3 Cyclosporine: Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg. The co-administration of LIPITOR with cyclosporine should be avoided [see Warnings and Precautions, Skeletal Muscle (5.1)].

7.4 Gemfibrozil: Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of LIPITOR with gemfibrozil should be avoided [see Warnings and Precautions (5.1)].

7.45 Other Fibrates: Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIPITOR should be administered with caution when used concomitantly with gemfibrozil or other fibrates [see Warnings and Precautions (5.1)].

7.5 Niacin: The risk of skeletal muscle effects may be enhanced when LIPITOR is used in combination with niacin; a reduction in LIPITOR dosage should be considered in this setting [see Warnings and Precautions (5.1)].

7.47 Rifampin or other Inducers of Cytochrome P450: Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.

7.57 Colchicine: Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X

LIPITOR is contraindicated in women who are or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy. Lipid lowering drugs offer no benefit during pregnancy because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy.

There are no adequate and well-controlled studies of atorvastatin use during pregnancy. There have been rare reports of congenital anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence. In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified.
Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m²) [see Contraindications, Pregnancy (4.3)].

In a study in rats given 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, neonate, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at 80 mg/day.

Statins may cause fetal harm when administered to a pregnant woman. LIPITOR should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes pregnant while taking LIPITOR, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus and the lack of known clinical benefit with continued use during pregnancy.

8.3 Nursing Mothers

It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother’s milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women requiring LIPITOR treatment should be advised not to nurse their infants [see Contraindications (4)].

8.4 Pediatric Use

Safety and effectiveness in patients 10-17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial of 6 months’ duration in adolescent boys and postmenarchal girls. Patients treated with LIPITOR had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were infections. Doses greater than 20 mg have not been studied in this patient population. In this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual cycle length in girls [see Clinical Studies (14.6); Adverse Reactions, Pediatric Patients (ages 10-17 years) (6.3); and Dosage and Administration, Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age) (2.2)]. Adolescent females should be counseled on appropriate contraceptive methods while on LIPITOR therapy [see Contraindications, Pregnancy (4.3) and Use in Specific Populations, Pregnancy (8.1)]. LIPITOR has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.

Clinical efficacy with doses up to 80 mg/day for 1 year have been evaluated in an uncontrolled study of patients with homozygous FH including 8 pediatric patients [see Clinical Studies, Homozygous Familial Hypercholesterolemia (14.5)].

8.5 Geriatric Use

Of the 39,828 patients who received LIPITOR in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for myopathy, LIPITOR should be prescribed with caution in the elderly.

8.6 Hepatic Impairment

Lipitor is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see Contraindications (4) and Pharmacokinetics (12.3)].

10 OVERDOSAGE

There is no specific treatment for LIPITOR overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance LIPITOR clearance.

11 DESCRIPTION
LIPITOR is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.

Atorvastatin calcium is \([R-(R^*, R^*)]-2-(4\text{-}fluorophenyl)-\beta,\delta\text{-}dihydroxy\text{-}5\text{-}(1\text{-}methyl ethyl)-3\text{-}phenyl\text{-}4\text{-}[\text{phenylamino}\text{-}carbonyl]\text{-}1\text{H}-\text{pyrrole}\text{-}1\text{-}heptanoic acid, calcium salt (2:1) trihydrate. The empirical formula of atorvastatin calcium is \((C_{33}H_{34}FN_2O_5)\cdot Ca\cdot 3H_2O\) and its molecular weight is 1209.42. Its structural formula is:

![Atorvastatin calcium structural formula](image)

Atorvastatin calcium is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol.

LIPITOR Tablets for oral administration contain 10, 20, 40, or 80 mg atorvastatin and the following inactive ingredients: calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apo B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles. LIPITOR reduces LDL-C in some patients with homozygous familial hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering medication(s).

A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C, and apo B (a membrane complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C.


Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not
consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.

12.2 Pharmacodynamics

LIPITOR, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see Dosage and Administration (2)].

12.3 Pharmacokinetics

Absorption: LIPITOR is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to LIPITOR dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether LIPITOR is given with or without food. Plasma LIPITOR concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see Dosage and Administration (2)].

Distribution: Mean volume of distribution of LIPITOR is approximately 381 liters. LIPITOR is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, LIPITOR is likely to be secreted in human milk [see Contraindications, Nursing Mothers (4.4) and Use in Specific Populations, Nursing Mothers (8.3)].

Metabolism: LIPITOR is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of LIPITOR. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of LIPITOR in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.1)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.

Excretion: LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of LIPITOR is recovered in urine following oral administration.

Specific Populations

Geriatric: Plasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see Use in Specific Populations, Geriatric Use (8.5)].

Pediatric: Pharmacokinetic data in the pediatric population are not available.

Gender: Plasma concentrations of LIPITOR in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with LIPITOR between men and women.

Renal Impairment: Renal disease has no influence on the plasma concentrations or LDL-C reduction of LIPITOR; thus, dose adjustment in patients with renal dysfunction is not necessary [see Dosage and Administration, Dosage in Patients with Renal Impairment (2.5), Warnings and Precautions, Skeletal Muscle (5.1)].

Hemodialysis: While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins.

Hepatic Impairment: In patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Contraindications (4.1)].

<table>
<thead>
<tr>
<th>Co-administered drug and Atorvastatin</th>
</tr>
</thead>
</table>

Reference ID: 3093302
<table>
<thead>
<tr>
<th>dosing regimen</th>
<th>Dose (mg)</th>
<th>Change in AUC</th>
<th>Change in Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>#Cyclosporine 5.2 mg/kg/day, stable dose</td>
<td>10 mg QD for 28 days</td>
<td>↑ 8.7 fold</td>
<td>↑ 10.7 fold</td>
</tr>
<tr>
<td>#Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td>10 mg, SD</td>
<td>↑ 9.4 fold</td>
<td>↑ 8.6 fold</td>
</tr>
<tr>
<td>#Telaprevir 750 mg q8h, 10 days</td>
<td>20 mg, SD</td>
<td>↑ 7.88 fold</td>
<td>↑ 10.6 fold</td>
</tr>
<tr>
<td>#Lopinavir 400 mg BID/ritonavir 100 mg BID, 14 days</td>
<td>20 mg QD for 4 days</td>
<td>↑ 5.9 fold</td>
<td>↑ 4.7 fold</td>
</tr>
<tr>
<td>#Ritonavir/Saquinarivir 400 mg BID/ritonavir 400mg BID, 15 days</td>
<td>40 mg QD for 4 days</td>
<td>↑ 3.9 fold</td>
<td>↑ 4.3 fold</td>
</tr>
<tr>
<td>#Clarithromycin 500 mg BID, 9 days</td>
<td>80 mg QD for 8 days</td>
<td>↑ 4.4 fold</td>
<td>↑ 5.4 fold</td>
</tr>
<tr>
<td>#Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days</td>
<td>10 mg QD for 4 days</td>
<td>↑ 3.4 fold</td>
<td>↑ 2.25 fold</td>
</tr>
<tr>
<td>#Itraconazole 200 mg QD, 4 days</td>
<td>40 mg SD</td>
<td>↑ 3.3 fold</td>
<td>↑ 20%</td>
</tr>
<tr>
<td>#Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
<td>↑ 2.53 fold</td>
<td>↑ 2.84 fold</td>
</tr>
<tr>
<td>#Fosamprenavir 1400 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
<td>↑ 2.3 fold</td>
<td>↑ 4.04 fold</td>
</tr>
<tr>
<td>#Nelfinavir 1250 mg BID, 14 days</td>
<td>10 mg QD for 28 days</td>
<td>↑ 74%</td>
<td>↑ 2.2 fold</td>
</tr>
<tr>
<td>#Grapefruit Juice, 240 mL QD *</td>
<td>40 mg, SD</td>
<td>↑ 37%</td>
<td>↑ 16%</td>
</tr>
<tr>
<td>Diltiazem 240 mg QD, 28 days</td>
<td>40 mg, SD</td>
<td>↑ 51%</td>
<td>No change</td>
</tr>
<tr>
<td>Erythromycin 500 mg QID, 7 days</td>
<td>10 mg, SD</td>
<td>↑ 33%</td>
<td>↑ 38%</td>
</tr>
<tr>
<td>Amlodipine 10 mg, single dose</td>
<td>80 mg, SD</td>
<td>↑ 15%</td>
<td>↑ 12%</td>
</tr>
<tr>
<td>Cimetidine 300 mg QD, 4 weeks</td>
<td>10 mg QD for 2 weeks</td>
<td>↓ Less than 1%</td>
<td>↓ 11%</td>
</tr>
<tr>
<td>Colestipol 10 mg BID, 28 weeks</td>
<td>40 mg QD for 28 weeks</td>
<td>↓ Not determined</td>
<td>↓ 26%**</td>
</tr>
<tr>
<td>Maalox TC® 30 mL QD, 17 days</td>
<td>10 mg QD for 15 days</td>
<td>↓ 33%</td>
<td>↓ 34%</td>
</tr>
<tr>
<td>Efavirenz 600 mg QD, 14 days</td>
<td>10 mg for 3 days</td>
<td>↓ 41%</td>
<td>↓ 1%</td>
</tr>
<tr>
<td>#Rifampin 600 mg QD, 7 days (co-administered) †</td>
<td>40 mg SD</td>
<td>↑ 30%</td>
<td>↑ 2.7 fold</td>
</tr>
<tr>
<td>#Rifampin 600 mg QD, 5 days (doses separated) ‡</td>
<td>40 mg SD</td>
<td>↓ 80%</td>
<td>↓ 40%</td>
</tr>
<tr>
<td>#Gemfibrozil 600mg BID, 7 days</td>
<td>40mg SD</td>
<td>↑ 35%</td>
<td>↓ Less than 1%</td>
</tr>
<tr>
<td>#Fenofibrate 160mg QD, 7 days</td>
<td>40mg SD</td>
<td>↑ 3%</td>
<td>↑ 2%</td>
</tr>
</tbody>
</table>

* Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).

† See Sections 5.1 and 7 for clinical significance.

‡ Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL - 1.2 liters per day).

** Single sample taken 8-16 h post dose.

Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.

The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.

**TABLE 4. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs**

<table>
<thead>
<tr>
<th>Atorvastatin</th>
<th>Co-administered drug and dosing regimen</th>
<th>Change in AUC</th>
<th>Change in Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>80 mg QD for 15 days</td>
<td>Antipyrine, 600 mg SD</td>
<td>↑ 3%</td>
<td>↓ 11%</td>
</tr>
<tr>
<td>80 mg QD for 14 days</td>
<td>Digoxin 0.25 mg QD, 20 days</td>
<td>↑ 15%</td>
<td>↑ 20 %</td>
</tr>
<tr>
<td>40 mg QD for 22 days</td>
<td>Oral contraceptive QD, 2 months - norethindrone 1 mg - ethinyl estradiol 35μg</td>
<td>↑ 28%</td>
<td>↑ 23%</td>
</tr>
</tbody>
</table>

Reference ID: 3093302
| 10 mg, SD | Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days | No change | No change |
| 10 mg QD for 4 days | Fosamprenavir 1400 mg BID, 14 days | ↓ 27% | ↓ 18% |
| 10 mg QD for 4 days | Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days | No change | No change |

* See Section 7 for clinical significance.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year carcinogenicity study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a rhabdomyosarcoma and, in another, there was a fibrosarcoma. This dose represents a plasma AUC (0-24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose.

A 2-year carcinogenicity study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in high-dose females. These findings occurred at plasma AUC (0–24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.

In *vitro*, atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation: the Ames test with *Salmonella typhimurium* and *Escherichia coli*, the HGPRT forward mutation assay in Chinese hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the *in vivo* mouse micronucleus test.

Studies in rats performed at doses up to 175 mg/kg (15 times the human exposure) produced no changes in fertility. There was aplasia and aspermia in the epididymis of 2 of 10 rats treated with 100 mg/kg/day of atorvastatin for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg and epididymal weight was lower at 100 mg/kg. Male rats given 100 mg/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of 10, 40, or 120 mg/kg for two years.

14 CLINICAL STUDIES

14.1 Prevention of Cardiovascular Disease

In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of LIPITOR on fatal and non-fatal coronary heart disease was assessed in 10,305 hypertensive patients 40–80 years of age (mean of 63 years), without a previous myocardial infarction and with TC levels ≤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age >55 years (84.5%), smoking (33.2%), diabetes (24.3%), history of CHD in a first-degree relative (26%), TC:HDL >6 (14.3%), peripheral vascular disease (5.1%), left ventricular hypertrophy (14.4%), prior cerebrovascular event (9.8%), specific ECG abnormality (14.3%), proteinuria/albuminuria (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-hypertensive therapy (Goal BP <140/90 mm Hg for non-diabetic patients; <130/80 mm Hg for diabetic patients) and allocated to either LIPITOR 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.

The effect of 10 mg/day of LIPITOR on lipid levels was similar to that seen in previous clinical trials.

LIPITOR significantly reduced the rate of coronary events [either fatal coronary heart disease (46 events in the placebo group vs. 40 events in the LIPITOR group) or non-fatal MI (108 events in the placebo group vs. 60 events in the LIPITOR group)] with a relative risk reduction of 36% ([based on incidences of 1.9% for LIPITOR vs. 3.0% for placebo], p=0.0005 (see Figure 1)). The risk reduction was consistent regardless of age, smoking status, obesity, or presence of renal dysfunction. The effect of LIPITOR was seen regardless of baseline LDL levels. Due to the small number of events, results for women were inconclusive.

**Figure 1:** Effect of LIPITOR 10 mg/day on Cumulative Incidence of Non-Fatal Myocardial Infarction or Coronary Heart Disease Death (in ASCOT-LLA)

Reference ID: 3093302
LIPITOR also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for LIPITOR and 2.3% for placebo). There was no significant difference between the treatment groups for death due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).

In the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of LIPITOR on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40–75 with type 2 diabetes based on WHO criteria, without prior history of cardiovascular disease and with LDL ≤ 160 mg/dL and TG ≤ 600 mg/dL. In addition to diabetes, subjects had 1 or more of the following risk factors: current smoking (23%), hypertension (80%), retinopathy (30%), or microalbuminuria (9%) or macroalbuminuria (3%). No subjects on hemodialysis were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either LIPITOR 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke. The primary analysis was the time to first occurrence of the primary endpoint.

Baseline characteristics of subjects were: mean age of 62 years, mean HbA1c 7.7%; median LDL-C 120 mg/dL; median TC 207 mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL.

The effect of LIPITOR 10 mg/day on lipid levels was similar to that seen in previous clinical trials.

LIPITOR significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the LIPITOR group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see Figure 2). An effect of LIPITOR was seen regardless of age, sex, or baseline lipid levels.

LIPITOR significantly reduced the risk of stroke by 48% (21 events in the LIPITOR group vs. 39 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the LIPITOR group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for angina, revascularization procedures, and acute CHD death.

There were 61 deaths in the LIPITOR group vs. 82 deaths in the placebo group (HR 0.73, p=0.059).

Figure 2: Effect of LIPITOR 10 mg/day on Time to Occurrence of Major Cardiovascular Event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) in CARDS
In the Treating to New Targets Study (TNT), the effect of LIPITOR 80 mg/day vs. LIPITOR 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident coronary heart disease who had achieved a target LDL-C level <130 mg/dL after completing an 8-week, open-label, run-in period with LIPITOR 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of LIPITOR and followed for a median duration of 4.9 years. The primary endpoint was the time-to-first occurrence of any of the following major cardiovascular events (MCVE): death due to CHD, non-fatal myocardial infarction, resuscitated cardiac arrest, and fatal and non-fatal stroke. The mean LDL-C, TC, TG, non-HDL, and HDL cholesterol levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of LIPITOR and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of LIPITOR.

Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002 (see Figure 3 and Table 5). The overall risk reduction was consistent regardless of age (<65, ≥65) or gender.

Figure 3: Effect of LIPITOR 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)
TABLE 5. Overview of Efficacy Results in TNT

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Atorvastatin 10 mg (N=5006)</th>
<th>Atorvastatin 80 mg (N=4995)</th>
<th>HR^a (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRIMARY ENDPOINT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First major cardiovascular event</td>
<td>n (%)</td>
<td>n (%)</td>
<td>0.78 (0.69, 0.89)</td>
</tr>
<tr>
<td>Components of the Primary Endpoint</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD death</td>
<td>127 (2.5)</td>
<td>101 (2.0)</td>
<td>0.80 (0.61, 1.03)</td>
</tr>
<tr>
<td>Non-fatal, non-procedure related MI</td>
<td>308 (6.2)</td>
<td>243 (4.9)</td>
<td>0.78 (0.66, 0.93)</td>
</tr>
<tr>
<td>Resuscitated cardiac arrest</td>
<td>26 (0.5)</td>
<td>25 (0.5)</td>
<td>0.96 (0.56, 1.67)</td>
</tr>
<tr>
<td>Stroke (fatal and non-fatal)</td>
<td>155 (3.1)</td>
<td>117 (2.3)</td>
<td>0.75 (0.59, 0.96)</td>
</tr>
<tr>
<td>SECONDARY ENDPOINTS*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First CHF with hospitalization</td>
<td>164 (3.3)</td>
<td>122 (2.4)</td>
<td>0.74 (0.59, 0.94)</td>
</tr>
<tr>
<td>First PVD endpoint</td>
<td>282 (5.6)</td>
<td>275 (5.5)</td>
<td>0.97 (0.83, 1.15)</td>
</tr>
<tr>
<td>First CABG or other coronary revascularization procedureb</td>
<td>904 (18.1)</td>
<td>667 (13.4)</td>
<td>0.72 (0.65, 0.80)</td>
</tr>
<tr>
<td>First documented angina endpointb</td>
<td>615 (12.3)</td>
<td>545 (10.9)</td>
<td>0.88 (0.79, 0.99)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>282 (5.6)</td>
<td>284 (5.7)</td>
<td>1.01 (0.85, 1.19)</td>
</tr>
<tr>
<td>Components of All-Cause Mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>155 (3.1)</td>
<td>126 (2.5)</td>
<td>0.81 (0.64, 1.03)</td>
</tr>
<tr>
<td>Noncardiovascular death</td>
<td>127 (2.5)</td>
<td>158 (3.2)</td>
<td>1.25 (0.99, 1.57)</td>
</tr>
<tr>
<td>Cancer death</td>
<td>75 (1.5)</td>
<td>85 (1.7)</td>
<td>1.13 (0.83, 1.55)</td>
</tr>
<tr>
<td>Other non-CV death</td>
<td>43 (0.9)</td>
<td>58 (1.2)</td>
<td>1.35 (0.91, 2.00)</td>
</tr>
<tr>
<td>Suicide, homicide, and other traumatic non-CV death</td>
<td>9 (0.2)</td>
<td>15 (0.3)</td>
<td>1.67 (0.73, 3.82)</td>
</tr>
</tbody>
</table>

a Atorvastatin 80 mg: atorvastatin 10 mg
b Component of other secondary endpoints
* Secondary endpoints not included in primary endpoint
HR=hazard ratio; CHD=coronary heart disease; CI=confidence interval; MI=myocardial infarction; CHF=congestive heart failure; CV=cardiovascular; PVD=peripheral vascular disease; CABG=coronary artery bypass graft
Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons

Of the events that comprised the primary efficacy endpoint, treatment with LIPITOR 80 mg/day significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal stroke, but not CHD death or resuscitated cardiac arrest (Table 5). Of the predefined secondary endpoints, treatment with LIPITOR 80 mg/day significantly reduced the rate of coronary revascularization, angina, and hospitalization for heart failure, but not peripheral vascular disease. The reduction in the rate of CHF with hospitalization was only observed in the 8% of patients with a prior history of CHF.

There was no significant difference between the treatment groups for all-cause mortality (Table 5). The proportions of subjects who experienced cardiovascular death, including the components of CHD death and fatal stroke, were numerically smaller in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group. The proportions of subjects who experienced noncardiovascular death were numerically larger in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group.

In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with LIPITOR 80 mg/day was compared to treatment with simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average LDL-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean LDL-C, TC, TG, HDL, and non-HDL cholesterol levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of LIPITOR and 105, 179, 142, 47, and 132 mg/dL during treatment with 20–40 mg of simvastatin.

There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, non-fatal MI, and resuscitated cardiac arrest): 411 (9.3%) in the LIPITOR 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI (0.78, 1.01), p=0.07.
There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the LIPITOR 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV death were similar for the LIPITOR 80 mg group and the simvastatin 20–40 mg group.

14.2 Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (*Fredrickson Types IIa and IIb*)

LIPITOR reduces total-C, LDL-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with hyperlipidemia and mixed dyslipidemia. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.

LIPITOR is effective in a wide variety of patient populations with hyperlipidemia, with and without hypertriglyceridemia, in men and women, and in the elderly.

In two multicenter, placebo-controlled, dose-response studies in patients with hyperlipidemia, LIPITOR given as a single dose over 6 weeks, significantly reduced total-C, LDL-C, apo B, and TG. (Pooled results are provided in Table 6.)

**TABLE 6. Dose Response in Patients With Primary Hyperlipidemia (Adjusted Mean % Change From Baseline)**

<table>
<thead>
<tr>
<th>Dose</th>
<th>N</th>
<th>TC</th>
<th>LDL-C</th>
<th>Apo B</th>
<th>TG</th>
<th>HDL-C</th>
<th>Non-HDL-C/ HDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>21</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>-3</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>22</td>
<td>-29</td>
<td>-39</td>
<td>-32</td>
<td>-19</td>
<td>6</td>
<td>-34</td>
</tr>
<tr>
<td>20</td>
<td>20</td>
<td>-33</td>
<td>-43</td>
<td>-43</td>
<td>-26</td>
<td>9</td>
<td>-41</td>
</tr>
<tr>
<td>40</td>
<td>21</td>
<td>-37</td>
<td>-50</td>
<td>-42</td>
<td>-29</td>
<td>6</td>
<td>-45</td>
</tr>
<tr>
<td>80</td>
<td>23</td>
<td>-45</td>
<td>-60</td>
<td>-50</td>
<td>-37</td>
<td>5</td>
<td>-53</td>
</tr>
</tbody>
</table>

*Results are pooled from 2 dose-response studies.*

In patients with *Fredrickson* Types IIa and IIb hyperlipoproteinemia pooled from 24 controlled trials, the median (25th and 75th percentile) percent changes from baseline in HDL-C for LIPITOR 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, LDL-C, TG, total-C/HDL-C, and LDL-C/HDL-C.

In three multicenter, double-blind studies in patients with hyperlipidemia, LIPITOR was compared to other statins. After randomization, patients were treated for 16 weeks with either LIPITOR 10 mg per day or a fixed dose of the comparative agent (Table 7).
### Table 7. Mean Percentage Change From Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)

<table>
<thead>
<tr>
<th>Treatment (Daily Dose)</th>
<th>N</th>
<th>Total-C</th>
<th>LDL-C</th>
<th>Apo B</th>
<th>TG</th>
<th>HDL-C</th>
<th>Non-HDL-C/HDLC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study 1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>707</td>
<td>-27a</td>
<td>-36a</td>
<td>-28a</td>
<td>-17a</td>
<td>+7</td>
<td>-37a</td>
</tr>
<tr>
<td>Lovastatin 20 mg</td>
<td>191</td>
<td>-19</td>
<td>-27</td>
<td>-20</td>
<td>-6</td>
<td>+7</td>
<td>-28</td>
</tr>
<tr>
<td>95% CI for Diffa</td>
<td></td>
<td>-9.2, -6.5</td>
<td>-10.7, -7.1</td>
<td>-10.0, -6.5</td>
<td>-15.2, -7.1</td>
<td>-1.7, 2.0</td>
<td>-11.1, -7.1</td>
</tr>
<tr>
<td><strong>Study 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>222</td>
<td>-25b</td>
<td>-35b</td>
<td>-27b</td>
<td>-17b</td>
<td>+6</td>
<td>-36b</td>
</tr>
<tr>
<td>Pravastatin 20 mg</td>
<td>77</td>
<td>-17</td>
<td>-23</td>
<td>-17</td>
<td>-9</td>
<td>+8</td>
<td>-28</td>
</tr>
<tr>
<td>95% CI for Diffb</td>
<td></td>
<td>-10.8, -6.1</td>
<td>-14.5, -8.2</td>
<td>-13.4, -7.4</td>
<td>-14.1, -0.7</td>
<td>-4.9, 1.6</td>
<td>-11.5, -4.1</td>
</tr>
<tr>
<td><strong>Study 3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPITOR 10 mg</td>
<td>132</td>
<td>-29c</td>
<td>-37c</td>
<td>-34c</td>
<td>-23c</td>
<td>+7</td>
<td>-39c</td>
</tr>
<tr>
<td>Simvastatin 10 mg</td>
<td>45</td>
<td>-24</td>
<td>-30</td>
<td>-30</td>
<td>-15</td>
<td>+7</td>
<td>-33</td>
</tr>
<tr>
<td>95% CI for Diffc</td>
<td></td>
<td>-8.7, -2.7</td>
<td>-10.1, -2.6</td>
<td>-8.0, -1.1</td>
<td>-15.1, -0.7</td>
<td>-4.3, 3.9</td>
<td>-9.6, -1.9</td>
</tr>
</tbody>
</table>

1 A negative value for the 95% CI for the difference between treatments favors LIPITOR for all except HDL-C, for which a positive value favors LIPITOR. If the range does not include 0, this indicates a statistically significant difference.

a Significantly different from lovastatin, ANCOVA, p ≤ 0.05
b Significantly different from pravastatin, ANCOVA, p ≤ 0.05
c Significantly different from simvastatin, ANCOVA, p ≤ 0.05

The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 7 is not known. Table 7 does not contain data comparing the effects of LIPITOR 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable.

### 14.3 Hypertriglyceridemia (Fredrickson Type IV)

The response to LIPITOR in 64 patients with isolated hypertriglyceridemia treated across several clinical trials is shown in the table below (Table 8). For the LIPITOR-treated patients, median (min, max) baseline TG level was 565 (267–1502).

### Table 8. Combined Patients With Isolated Elevated TG: Median (min, max) Percentage Change From Baseline

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=12)</th>
<th>LIPITOR 10 mg (N=37)</th>
<th>LIPITOR 20 mg (N=13)</th>
<th>LIPITOR 80 mg (N=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides</td>
<td>-12.4 (-36.6, 82.7)</td>
<td>-41.0 (-76.2, 49.4)</td>
<td>-38.7 (-62.7, 29.5)</td>
<td>-51.8 (-82.8, 41.3)</td>
</tr>
<tr>
<td>Total-C</td>
<td>-2.3 (-15.5, 24.4)</td>
<td>-28.2 (-44.9, -6.8)</td>
<td>-34.9 (-49.6, -15.2)</td>
<td>-44.4 (-63.5, -3.8)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>3.6 (-31.3, 31.6)</td>
<td>-26.5 (-57.7, 9.8)</td>
<td>-30.4 (-53.9, 0.3)</td>
<td>-40.5 (-60.6, -13.8)</td>
</tr>
<tr>
<td>HDL-C</td>
<td>3.8 (-18.6, 13.4)</td>
<td>13.8 (-32.2, 61.5)</td>
<td>11.0 (-3.7, 25.2)</td>
<td>7.5 (-10.8, 37.2)</td>
</tr>
<tr>
<td>VLDL-C</td>
<td>-1.0 (-31.9, 53.2)</td>
<td>-48.8 (-85.8, 57.3)</td>
<td>-44.6 (-62.2, -10.8)</td>
<td>-62.0 (-88.2, 37.6)</td>
</tr>
<tr>
<td>non-HDL-C</td>
<td>-2.8 (-17.6, 30.0)</td>
<td>-33.0 (-52.1, -13.3)</td>
<td>-42.7 (-53.7, -17.4)</td>
<td>-51.5 (-72.9, -4.3)</td>
</tr>
</tbody>
</table>

### 14.4 Dysbetalipoproteinemia (Fredrickson Type III)

The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia (Fredrickson Type III) are shown in the table below (Table 9).

### Table 9. Open-Label Crossover Study of 16 Patients With Dysbetalipoproteinemia (Fredrickson Type III)

<table>
<thead>
<tr>
<th></th>
<th>Median (min, max) at Baseline (mg/dL)</th>
<th>Median % Change (min, max)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LIPITOR 10 mg (N=13)</td>
<td>LIPITOR 80 mg (N=14)</td>
</tr>
<tr>
<td>Total-C</td>
<td>442 (225, 1320)</td>
<td>-37 (-85, 17)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>678 (273, 5990)</td>
<td>-39 (-92, -8)</td>
</tr>
<tr>
<td>LDL-C + VLDL-C</td>
<td>215 (111, 613)</td>
<td>-32 (-76, 9)</td>
</tr>
<tr>
<td>non-HDL-C</td>
<td>411 (218, 1272)</td>
<td>-43 (-87, -19)</td>
</tr>
</tbody>
</table>
14.5 Homozygous Familial Hypercholesterolemia

In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of LIPITOR. The mean LDL-C reduction in this study was 18%. Twenty-five patients with a reduction in LDL-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in LDL-C. Five of the 29 patients had absent LDL-receptor function. Of these, 2 patients also had a portacaval shunt and had no significant reduction in LDL-C. The remaining 3 receptor-negative patients had a mean LDL-C reduction of 22%.

14.6 Heterozygous Familial Hypercholesterolemia in Pediatric Patients

In a double-blind, placebo-controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolemia (FH) or severe hypercholesterolemia, were randomized to LIPITOR (n=140) or placebo (n=47) for 26 weeks and then all received LIPITOR for 26 weeks. Inclusion in the study required 1) a baseline LDL-C level ≥ 190 mg/dL or 2) a baseline LDL-C level ≥ 160 mg/dL and positive family history of FH or documented premature cardiovascular disease in a first or second-degree relative. The mean baseline LDL-C value was 218.6 mg/dL (range: 138.5–385.0 mg/dL) in the LIPITOR group compared to 230.0 mg/dL (range: 160.0–324.5 mg/dL) in the placebo group. The dosage of LIPITOR (once daily) was 10 mg for the first 4 weeks and uptitrated to 20 mg if the LDL-C level was > 130 mg/dL. The number of LIPITOR-treated patients who required uptitration to 20 mg after Week 4 during the double-blind phase was 80 (57.1%).

LIPITOR significantly decreased plasma levels of total-C, LDL-C, triglycerides, and apolipoprotein B during the 26-week double-blind phase (see Table 10).

TABLE 10. Lipid-altering Effects of LIPITOR in Adolescent Boys and Girls with Heterozygous Familial Hypercholesterolemia or Severe Hypercholesterolemia (Mean Percentage Change From Baseline at Endpoint in Intention-to-Treat Population)

<table>
<thead>
<tr>
<th>DOSAGE</th>
<th>N</th>
<th>Total-C</th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>TG</th>
<th>Apolipoprotein B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>47</td>
<td>-1.5</td>
<td>-0.4</td>
<td>-1.9</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>LIPITOR</td>
<td>140</td>
<td>-31.4</td>
<td>-39.6</td>
<td>2.8</td>
<td>-12.0</td>
<td>-34.0</td>
</tr>
</tbody>
</table>

The mean achieved LDL-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in the LIPITOR group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the placebo group during the 26-week double-blind phase.

The safety and efficacy of doses above 20 mg have not been studied in controlled trials in children. The long-term efficacy of LIPITOR therapy in childhood to reduce morbidity and mortality in adulthood has not been established.

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

10 mg tablets: coded “PD 155” on one side and “10” on the other.
NDC 0071-0155-23 bottles of 90
NDC 0071-0155-34 bottles of 5000
NDC 0071-0155-40 10 x 10 unit dose blisters

20 mg tablets: coded “PD 156” on one side and “20” on the other.
NDC 0071-0156-23 bottles of 90
NDC 0071-0156-40 10 x 10 unit dose blisters
NDC 0071-0156-94 bottles of 5000

40 mg tablets: coded “PD 157” on one side and “40” on the other.
NDC 0071-0157-23 bottles of 90
NDC 0071-0157-73 bottles of 500
NDC 0071-0157-88 bottles of 2500
NDC 0071-0157-40 10 x 10 unit dose blisters
80 mg tablets: coded “PD 158” on one side and “80” on the other.
NDC 0071-0158-23 bottles of 90
NDC 0071-0158-73 bottles of 500
NDC 0071-0158-88 bottles of 2500
NDC 0071-0158-92 8 x 8 unit dose blisters

Storage
Store at controlled room temperature 20 - 25°C (68 - 77°F) [see USP].

17 PATIENT COUNSELING INFORMATION

Patients taking LIPITOR should be advised that cholesterol is a chronic condition and they should adhere to their medication along with their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program as appropriate, and periodic testing of a fasting lipid panel to determine goal attainment.

Patients should be advised about substances they should not take concomitantly with atorvastatin [see Warnings and Precautions (5.1)]. Patients should also be advised to inform other healthcare professionals prescribing a new medication that they are taking LIPITOR.

17.1 Muscle Pain
All patients starting therapy with LIPITOR should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness, or weakness. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (>1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.

17.2 Liver Enzymes
It is recommended that liver function enzyme tests be performed prior to and at 12 weeks following both before the initiation of therapy LIPITOR and any elevation of dose, and periodically (e.g., semiannually) thereafter if signs or symptoms of liver injury occur. All patients treated with LIPITOR should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.

17.3 Pregnancy
Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using LIPITOR. Discuss future pregnancy plans with your patients, and discuss when to stop LIPITOR if they are trying to conceive. Patients should be advised that if they become pregnant, they should stop taking LIPITOR and call their healthcare professional.

17.4 Breastfeeding
Women who are breastfeeding should be advised to not use LIPITOR. Patients who have a lipid disorder and are breastfeeding, should be advised to discuss the options with their healthcare professional.

Rx Only

Manufactured by:
Pfizer Ireland Pharmaceuticals
Dublin, Ireland

Distributed by:
Pfizer
Parke-Davis
Division of Pfizer Inc, NY, NY 10017

Reference ID: 3093302
PATIENT INFORMATION

LIPITOR
atorvastatin calcium tablets
(LIP-ih-tore)

Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

If you have any questions about LIPITOR, ask your doctor or pharmacist.

What is LIPITOR?
LIPITOR is a prescription medicine that lowers cholesterol in your blood. It lowers the LDL-C ("bad" cholesterol) and triglycerides in your blood. It can raise your HDL-C ("good" cholesterol) as well. LIPITOR is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone.

LIPITOR can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as:
- age, smoking, high blood pressure, low HDL-C, heart disease in the family.

LIPITOR can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as:
- eye problems, kidney problems, smoking, or high blood pressure.

LIPITOR starts to work in about 2 weeks.

What is Cholesterol?
Cholesterol and triglycerides are fats that are made in your body. They are also found in foods. You need some cholesterol for good health, but too much is not good for you. Cholesterol and triglycerides can clog your blood vessels. It is especially important to lower your cholesterol if you have heart disease, smoke, have diabetes or high blood pressure, are older, or if heart disease starts early in your family.

Who Should Not Take LIPITOR?

Do not take LIPITOR if you:
- are pregnant or think you may be pregnant, or are planning to become pregnant. Lipitor may harm your unborn baby. If you get pregnant, stop taking LIPITOR and call your doctor right away.
- are breast feeding. LIPITOR can pass into your breast milk and may harm your baby.
- have liver problems.
- are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.

LIPITOR has not been studied in children under 10 years of age.

Before You Start LIPITOR
Tell your doctor if you:
- have muscle aches or weakness
- drink more than 2 glasses of alcohol daily
- have diabetes
- have a thyroid problem
- have kidney problems

Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:
- your immune system
- cholesterol
- infections
- birth control
- heart failure
- HIV or AIDS

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

How Should I Take LIPITOR?

- Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your cholesterol levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these blood test results.

- Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.

Don't break LIPITOR tablets before taking.

- Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.

- If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.

- If you take too much LIPITOR or overdose, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.

What Should I Avoid While Taking LIPITOR?

- Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.

- Do not get pregnant. If you get pregnant, stop taking LIPITOR right away and call your doctor.

What are the Possible Side Effects of LIPITOR?

LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include:
• **Muscle problems.** LIPITOR can cause serious muscle problems that can lead to kidney problems, including kidney failure. You have a higher chance for muscle problems if you are taking certain other medicines with LIPITOR.

• **Liver problems.** LIPITOR can cause liver problems. Your doctor should do blood tests to check your liver before you start taking LIPITOR, and while you take it, if you have symptoms of liver problems while you take LIPITOR. Call your doctor right away if you have the following symptoms of liver problems:
  - feel tired or weak
  - loss of appetite
  - upper belly pain
  - dark amber colored urine
  - yellowing of your skin or the whites of your eyes

Call your doctor right away if you have:

- muscle problems like weakness, tenderness, or pain that happen without a good reason, especially if you also have a fever or feel more tired than usual.
- allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away.
- nausea and vomiting.
- passing brown or dark-colored urine.
- you feel more tired than usual
- your skin and whites of your eyes get yellow.
- stomach pain.
- allergic skin reactions.

In clinical studies, patients reported the following common side effects while taking LIPITOR: diarrhea, upset stomach, muscle and joint pain, and alterations in some laboratory blood tests.

The following additional side effects have been reported with LIPITOR:

- tiredness, and tendon problems, memory loss, and confusion.

Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.

These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.

**How do I store LIPITOR**

- Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).
- Do not keep medicine that is out of date or that you no longer need.
- Keep LIPITOR and all medicines out of the reach of children.

**General Information About LIPITOR**

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at [www.lipitor.com](http://www.lipitor.com).

**What are the Ingredients in LIPITOR?**

**Active Ingredient:** atorvastatin calcium

**Inactive Ingredients:** calcium carbonate, USP; candelilla wax, FCC; croscarmellose sodium, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
020702Orig1s060

MEDICAL REVIEW(S)
On August 11, 2011 the Division of Metabolism and Endocrinology Products (DMEP) issued supplement request letters to the sponsors of all HMG-CoA reductase inhibitor (statin) drugs requesting changes to the labeling so as to furnish adequate information for the safe and effective use of their statin. These labeling changes were based on FDA’s comprehensive review of the statin class of drugs, including clinical trial data, Adverse Event Reporting System (AERS) reports, the published literature, and the labels of other approved drugs containing information on statin co-administration. This review will serve to summarize the safety issues and the sources and reviews of the data.

1. Liver enzyme abnormalities – TSI #57

On March 19, 2007 DMEP opened Tracked Safety Issue (TSI) #57 to evaluate hepatotoxicity associated with the statin class of drugs. This was based on articles in the published literature which suggested that FDA should re-evaluate current recommendations in statin labeling for routine periodic monitoring of liver enzyme tests.

In March 2008, DMEP issued Information Request letters to the statin sponsors requesting the following:

a. Does <<APPLICANT>> have an opinion or recommendation regarding the utility of baseline and/or periodic monitoring of serum aminotransferase activity prior to and/or during treatment with <<STATIN>>? Please address this question for subjects with normal liver function and for those with asymptomatic liver disease (e.g., NAFLD, hepatitis C).

b. Upon what clinical evidence or other consideration are these opinions or recommendations based?

c. Please provide the number of phase 2 and 3 trials conducted with <<STATIN>> for which you have access to the raw data.

The table below summarizes the sponsors’ responses to the first question:
In general, most sponsors agreed that liver enzyme testing prior to initiation of statin therapy was appropriate, but acknowledged that there appeared to be limited utility to routine liver biochemistry monitoring during treatment. One sponsor commented on the recommendations of the Liver Expert Panel convened by the National Lipid Association which stated that “because there is no evidence that a relation exists between elevated serum aminotransferase levels and significant liver injury, or that routine monitoring of liver biochemistries will identify individuals likely to develop rare cases of idiosyncratic liver failure, the requirement for routine liver biochemistry monitoring in patients receiving any of the currently marketed statin therapies should be re-examined.” Another sponsor noted that “nearly 50% of hyperlipidemic patients have coexisting non-alcoholic fatty liver disease (NAFLD) and it is well known that LFT levels fluctuate in NAFLD.”

In conjunction with the request to statin sponsors, DMEP requested that the Office of Surveillance and Epidemiology (OSE) conduct a review to characterize the risk of clinically serious hepatotoxicity in association with statins and assist in a determination if the statin class labeling for liver enzyme monitoring should be retained, revised, or removed. OSE had conducted 5 postmarket reviews of statins and hepatotoxicity between 2000 and 2009. Those reviews had consistently noted that reporting of statin-associated serious liver injury to AERS was extremely low (reporting rate of \( \leq 2 \) per one million patient-years).

The OSE review of AERS was completed May 13, 2011. The review focused on cases of severe liver injury, defined as a 4 (severe liver injury) or a 5 (death or liver transplant) using the Drug Induced Liver Injury Network (DILIN) liver injury severity scale. Cases meeting those criteria were further assessed for causality. Seventy-five cases (27 with a severity score of 4 and 48 with a severity score of 5 [37 deaths and 11 liver transplants]) were assessed for causality, 30 of which (14 deaths, 7 liver transplantations, and 9 severe liver injury) were assessed as possibly (25-49% likelihood) or probably (50-74% likelihood) associated with

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Product</th>
<th>Text suggests interest in withdrawal of monitoring</th>
<th>caveats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrx</td>
<td>Lovastatin ER</td>
<td>No</td>
<td>none</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>rosuvastatin</td>
<td>Yes</td>
<td>none</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>pravastatin</td>
<td>N/A</td>
<td>No text to delete</td>
</tr>
<tr>
<td>Merck</td>
<td>lovastatin</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>Merck</td>
<td>simvastatin</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>Novartis</td>
<td>fluvastatin</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>Pfizer</td>
<td>atorvastatin</td>
<td>Yes</td>
<td>10 mg dose only</td>
</tr>
</tbody>
</table>

Reference ID: 3093395
statin therapy. No cases were assessed as highly likely (75-95% likelihood) or definitely (>95% likelihood) associated with statin therapy. OSE noted that “despite rising use of statins as a class since the late 1990s, there has not been a detectable uptick in the annual rates of fatal (deaths or liver transplant) or severe liver injury possibly or probably causally associated cases.” The cases are summarized in the table below:

<table>
<thead>
<tr>
<th>Table 6. Characteristics of U.S. AERS Cases With A Liver Injury Severity Score of 4 (Severe) or 5 (Death or Transplant) and Causally Associated* With Statin Therapy. Source: AERS, marketing through January 1, 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver Injury Severity Score</td>
</tr>
<tr>
<td># of Cases</td>
</tr>
<tr>
<td>Median Age in Years (range)</td>
</tr>
<tr>
<td>Percent Female</td>
</tr>
<tr>
<td>Statin at the Time of Event: Median Daily Dose in mg (range [n])</td>
</tr>
<tr>
<td>Atorvastatin</td>
</tr>
<tr>
<td>Cerivastatin</td>
</tr>
<tr>
<td>Fluvastatin</td>
</tr>
<tr>
<td>Lovastatin</td>
</tr>
<tr>
<td>Pravastatin</td>
</tr>
<tr>
<td>Rosuvastatin</td>
</tr>
<tr>
<td>Simvastatin</td>
</tr>
<tr>
<td>Time to Onset in Months**, Median (range)</td>
</tr>
<tr>
<td>Peak Serum Total Bilirubin Level in mg/dL, Median (range [n])</td>
</tr>
<tr>
<td>Peak Serum ALT Level in units/L, Median (range [n])</td>
</tr>
<tr>
<td>Peak Serum AST Level in units/L, Median (range [n])</td>
</tr>
<tr>
<td>Peak Serum ALP Level in units/L, Median (range [n])</td>
</tr>
</tbody>
</table>

*Defined as probably associated (supported by the evidence as implicating the drug but not definite or highly likely) or possibly associated (causality is not supported by the preponderance of evidence, but one cannot definitively exclude the possibility)

**Time to onset defined as the interval between exposure time or time after dose increased to reported liver injury event

OSE also looked at cases from the DILIN and Acute Liver Failure Study Group (ALFSG), organizations which have been systematically submitting reports to FDA of drug associated liver injury referred to their respective liver injury outcome studies. For statin associated liver injury, DILIN has submitted 25 reports to FDA as of January 1, 2011, twelve of which resulted in an outcome of hospitalization. In the ALFSG database, there were 9 reports of drug-induced liver injury (DILI) associated with statin therapy. OSE cited a 2010 article from
ALFSG that included 133 prospectively identified cases of idiopathic DILI resulting in acute liver failure. Fifteen patients were taking statins and in 6 of these 15 individuals a statin was identified as the only potential DILI agent. The authors noted that statin hepatotoxicity is “generally benign” and the identification of these 6 cases represents a “provocative observation”.

Using the AERS and drug utilization databases, reporting rates were calculated for U.S. statin cases associated with liver injury and an outcome of death or liver transplant, from the time of initial marketing approval through January 1, 2009. It should be noted that reporting rates are subject to secular reporting trends which normally preclude generation of reporting rates between products with initial marketing dates greater than 2-4 years apart. Despite the limitations of the analysis, it appears that reporting levels for serious liver injury in association with currently marketed statins are generally similar.

<table>
<thead>
<tr>
<th>Generic Name (Brand)</th>
<th>Number of cases</th>
<th>Total Number of Prescriptions (TRxs) Dispensed by U.S. Retail Pharmacies, 1991-2008$ (in millions)</th>
<th>Observed reporting rate as cases per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovastatin (Mevacor, Advicor, Altocor)</td>
<td>23</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td>Pravastatin (Pravachol)</td>
<td>11</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td>Simvastatin (Zocor, Vytorin, Simcor)</td>
<td>51</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td>Fluvastatin (Lescol)</td>
<td>4</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td>Atorvastatin (Lipitor)</td>
<td>64</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td>Rosuvastatin (Crestor)</td>
<td>3</td>
<td></td>
<td>(0)(0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>156</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OSE also reviewed current monitoring guidelines including the National Lipid Association’s Liver Expert Panel, which state:

*The Liver Expert Panel does not believe that the available scientific evidence supports the routine monitoring of liver biochemistries in asymptomatic patients receiving statins. The Panel makes this recommendation because (1) irreversible liver damage resulting from statins is exceptionally rare and is likely idiosyncratic in nature, and (2) no data exist to show that routine monitoring of liver biochemistries is effective in identifying the very rare individual who may develop significant liver injury from ongoing statin therapy. In the view of the Panel, routine monitoring will instead identify patients with isolated*
increased aminotransferase levels, which could motivate physicians to alter or discontinue statin therapy, thereby placing patients at increased risk for cardiovascular events.

OSE further noted that the NLA’s Statin Safety Task Force had a slightly divergent opinion and made the following recommendation:

Until there is a change in the FDA-approved prescribing information for statins, it is appropriate to continue to measure transaminase levels before starting therapy, 12 weeks after initiating therapy, after a dose increase, and periodically thereafter. However, routine monitoring of liver function tests is not supported by the available evidence and the current recommendation for monitoring needs to be reconsidered by the FDA.

The OSE review concluded:

Serious, hepatocellular DILI can be caused by statins. Although the routine monitoring of serum ALT and other markers for liver injury is vital for drug development, it does not appear to be useful in a post-marketing, non-study, ambulatory setting to routinely detect and prevent serious liver injury in association with statins. In place of current recommendations for serum enzyme monitoring, labeling for statins should focus on an alert to identify serious liver injury and clinical symptoms of liver injury, interruption of therapy, physician interactions, and emphasize the importance of appropriate diagnostic workup.

OSE further recommended:

It is justified that the recommendation to perform routine periodic serum ALT monitoring in all treated patients at prespecified intervals currently in place for some marketed statins be removed.

Based on these recommendations, DMEP requested the following changes to statin labeling:

Under HIGHLIGHTS OF PRESCRIBING INFORMATION, under WARNINGS AND PRECAUTIONS:

Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.

Under 5 WARNINGS AND PRECAUTIONS,

It is recommended that liver enzyme tests be performed before the initiation of <<STATIN>>.

There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including <<STATIN>>. If serious liver injury with clinical symptoms and/or
hyperbilirubinemia or jaundice occurs during treatment with <<STATIN>>, promptly interrupt therapy. If an alternate etiology is not found do not restart <<STATIN>>.

Under 6 ADVERSE REACTIONS, Post-Marketing Experience:

Under 17 PATIENT COUNSELING INFORMATION, Liver Enzymes:

It is recommended that liver enzyme tests be before the initiation of <<STATIN>> and if signs or symptoms of liver injury occur. All patients treated with <<STATIN>> should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.

2. Cognitive effects – TSI #772

On September 2, 2009 DMEP opened TSI #772 to evaluate the effect of statins on cognition. This was based on a complaint received from Joe Graedon of the People’s Pharmacy, and an unpublished study by Duane Graveline, M.D., M.P.H. and Jay S. Cohen, M.D. entitled “Lipitor-associated memory loss: analysis of 662 cases of cognitive damage”, as well as other articles from the published literature.

In attempting to assess this risk, DMEP looked initially at pre-clinical data. Several of the statin drug sponsors had performed pre-clinical cognition studies; however, those studies only address the issue of dementia syndromes, and are less helpful in addressing the issue of acute confusional states or memory impairment. Therefore, it was determined that there was no value added to re-assessing the pre-clinical data.

DMEP sent information request letters to those statin sponsors who had conducted clinical trials in which some form of neurocognitive assessment had been conducted as part of the study protocol. Those trials included: Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Heart Protection Study (HPS), and Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).

The findings were as follows:

- **PROSPER:** Subjects were screened with a Mini Mental Status Exam (MMSE) and excluded if their score was <24. Cognitive function was assessed in all 5,804 participants at six different time points during the study.
Four neuropsychological tests were performed, two of which tested executive function (attention and speed) and two of which tested memory (immediate and delayed). All tests showed a significant decline over time (3-year follow-up); however, there was no difference between treatment groups, pravastatin 40 mg versus placebo.

- **HPS:** A modified Telephone Interview for Cognitive Status (TICS-m) questionnaire was administered to participants during their final follow-up, either face-to-face in the clinic or over the telephone. Data were available on 8086/10269 (79%) of simvastatin-allocated subjects and 7834/10267 (76%) of placebo-allocated subjects. No significant differences were observed between the treatment groups in the percentages of participants classified as cognitively impaired (defined as a TICS-m score below 22 out of 39), either overall (23.7% simvastatin 40 mg-allocated vs. 24.2% placebo-allocated) or in subgroups defined with respect to their age at study entry (<65 years: 17.1% vs. 17.8%; 65-69 years: 25.8% vs. 25.4%; 70-80 years: 34.6% vs. 36.2%) or their previous history of cerebrovascular disease (no prior stroke: 22.8% vs. 23.3%; prior stroke: 31.9% vs. 33.3%). Nor was there any significant difference between the groups in mean TICS-m score (24.08 vs. 24.06). Similar numbers of participants in each treatment group were reported to have developed dementia during follow-up (31 [0.3%] vs. 31 [0.3%]).

There was a slightly higher frequency of cases of Alzheimer’s disease or Alzheimer’s type dementia in patients on simvastatin (n=6) compared to placebo (n=3). When looking at all patients with potential diagnoses of dementia including Alzheimer’s disease, confusion, disorientation, dementia or cognitive impairment, there was no difference in the frequency of patients in the simvastatin group (n=35; 0.34%) compared to placebo (n=33; 0.32%).

- **SEARCH:** Assessment of cognitive function, using the TICS-m score, was a tertiary endpoint for the folate arm of the trial. It was performed in 8891 subjects – 4473 on simvastatin 80 mg and 4418 on simvastatin 20 mg – at the final visit. There was no difference in mean TICS-m score between treatment groups (24.3 ± 4.1 for simvastatin 80 mg vs. 24.3 ± 4.3 for simvastatin 20 mg), and no difference in percentages of patients with scores <20, ≥20, <22, ≥22, <25, ≥25, <30, ≥30 between treatment groups. The TICS-m score reflects memorizing ability in large part. Verbal fluency scores also did not differ among patients allocated to simvastatin 80 mg and simvastatin 20 mg. Hearing thresholds were assessed at final follow-up and did not differ between the simvastatin groups.

The incidence of memory loss attributed to study treatment was 17 (0.3%) in patients allocated to simvastatin 80 mg, and 8 (0.1%) in patients allocated to simvastatin 20 mg.

It should also be noted that while no formal neurocognitive assessment was performed in the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), there was noted a
statistically significant increase in the reported adverse event of confusional state in subjects allocated to rosuvastatin 20 mg (n=8 [0.2%]) versus subjects allocated to placebo (n=4 [0.04%]).

DMEP was aware of a Phase III efficacy study of atorvastatin that had been conducted in patients with mild to moderate Alzheimer’s Disease. The clinical study report for this study (Study A2581078) was requested from the sponsor and consulted to the Division of Neurology Products (DNP) for review. DNP’s findings were as follows:

The results of Study A2581078, an adequately-designed Phase III efficacy and safety study of atorvastatin (Lipitor) in patients with mild to moderate Probable Alzheimer’s Disease, provide no evidence that the administration of Lipitor results in cognitive worsening in this population; neither was there any evidence of a worsening of global function in those treated with atorvastatin in this study.

DMEP consulted OSE and requested that a review of AERS and the published literature be conducted to further assess the effect of statins on cognition. In 2002, OSE had performed a review of 279 statin reports associated with transient memory loss. This review had been requested by DMEP in response to a consumer report of transient global amnesia (TGA) with atorvastatin. At that time, OSE determined that the calculated reporting rate for statin-associated TGA (0.12-0.55 per 100,000 patient years) was well below the background incidence rate (3.4-32/100,000 population per year). As memory loss was already included in the statin labels, no labeling change was recommended at that time.

OSE’s updated review of AERS focused on reports of serious cases of memory impairment, using the following High Level Terms (HLT):

- Mental Impairment (excluding dementia and memory loss)
- Memory Loss (excluding dementia)
- Amnestic Symptoms
- Confusion and Disorientation

Through January 1, 2011 there were 1,698 U.S. serious reports (crude counts) in AERS.
Further case review was limited to 182 reports received by FDA in 2010. Of those reports, 57 unique cases described transient cognitive change as the primary adverse event. Sixty-nine percent (n=125) of the cases were excluded because they reported multiple events such as rhabdomyolysis, renal failure, and confusion (n=81), were duplicates (n=18), hearsay (n=3), reported by attorneys (n=5), or solicited reports (n=16).

Characteristics of the 57 cases included:
- Age: median of 62 years (30-85)
- Sex: 62% male
- Exposure time: median of 3 years (1 month-12 years)

The literature review included case series of transient cognitive impairment associated with statin use, as well as observational studies on the association between statin use and the incidence of dementia. The observational evidence was summarized based on a meta-analysis by Zhou and colleagues:

After conducting a systematic review, the authors identified four cohort studies and three case-control studies which examined the association between statin use and dementia. The average observation period ranged from three to nine years. Three case-control studies suggested statin use may lower the incidence of dementia; while the remaining four cohort studies failed to demonstrate an association between statin use and incident dementia. A pooled analysis also failed to demonstrate an association between statin use and incident dementia.

OSE further noted:
Results from three prospective cohort studies published within the last year provide similar conflicting results. Analyses of Baltimore Longitudinal Study of Aging and the Ginkgo Evaluation of Memory Study suggested that statin use is associated with a lower risk of dementia. A nested case control study in the Neurological Disorders in Central Spain cohort failed to detect an association between statin use and cross-sectional performance on a neuropsychological test battery.

<table>
<thead>
<tr>
<th>Author</th>
<th>Study Design</th>
<th>Total Sample Size (% Exposed to Statins)</th>
<th>Outcome</th>
<th>Key Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou (2007)</td>
<td>Meta-Analysis – Observational Studies</td>
<td>105.23 (12%)</td>
<td>Incident Dementia</td>
<td>Adjusted OR=0.77 (95%: 0.45-1.30)</td>
</tr>
<tr>
<td>Beydoun (2010)</td>
<td>Cohort Study</td>
<td>1604 (7%)</td>
<td>Incident Dementia</td>
<td>Adjusted HR=0.21 (95%: 0.09-0.48)</td>
</tr>
<tr>
<td>Betterman (2011)</td>
<td>Cohort Study</td>
<td>3069 (25%)</td>
<td>Incident Dementia</td>
<td>Adjusted HR=0.79 (95%: 0.65-0.96)</td>
</tr>
<tr>
<td>Benito-Leon (2010)</td>
<td>Nested Case-Control</td>
<td>548 (25%)</td>
<td>Neuropsychological Test Performance</td>
<td>No treatment effect observed in any test neuropsychological test administered (global cognition, verbal fluency, psychomotor speed, confrontational naming, verbal memory, logical memory)</td>
</tr>
</tbody>
</table>

OSE concluded:

The postmarket statin reports associated with transient cognitive change generally describe individuals over the age of 50 years who experience notable (sometimes described as “dramatic”), but ill-defined memory loss or impairment (e.g., “lost my mind”) that is reversible upon discontinuation of statin therapy. The statin exposure time to onset of the event is highly variable (1 day to years). These cases do not appear to be associated with fixed or progressive dementia, such as Alzheimer’s disease.
Like the previous (2002) OSE review, the analyzed data in this review did not reveal any discernible dose–event or age (the reported age at the time of event is similar to the age of the population using statins) trends or effects between statins and other drugs; few reports described neurologic follow-up or standardized testing results. Findings from this review (and the 2002 OSE review) are also similar to patient survey results recently published by the University of California San Diego (UCSD) Statin Effects Study investigators. Cognitive issues were reported for all statins, with atorvastatin and simvastatin most frequently reported. The time to onset was variable (1 day to 10 years). Ninety percent reported symptom improvement after the statin was discontinued. Complete recovery time varied from 1 day to several years (median time to first noted improvement was 2.5 weeks). Of 29 participants who underwent rechallenge, 19 reported recurrence of events.

An analysis of the epidemiologic evidence and clinical trials did not provide evidence that chronic statin use is associated with cognitive decline at the population level. Two studies demonstrated that exposure to statins for up to six months may prevent the acquisition of a practice effect on select neuropsychological measures. However, the clinical significance of an absent practice effect in the context of normal cognitive performance is questionable. Furthermore, no study systematically assessed patients who experienced statin-associated cognitive impairment during both dechallenge and rechallenge. Such systematic studies would provide additional evidence to support a causal association and better characterize the clinical phenotype.

OSE recommended that DMEP consider statin class labeling that would characterize the nature of the cognitive changes. In response, DMEP requested that the following be added to the Adverse Reactions, Postmarketing Experience sub-section of all statin labels:

There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

3. Drug-drug interaction with protease inhibitors – TSI #756

On July 23, 2009 TSI #756 was opened to examine the drug-drug interaction between statins and protease inhibitors.
In July 2009, the sponsor for rosuvastatin (CRESTOR) submitted a prior approval supplement (PAS) proposing to include information on increased rosuvastatin exposure when CRESTOR was co-administered with the combinations of protease inhibitors tipranavir/ritonavir, atazanavir/ritonavir or fosamprenavir/ritonavir, based on studies in the published literature. Previous CRESTOR labeling had noted a DDI with lopinavir/ritonavir (KALETRA) resulting in a dose cap of 10 mg of CRESTOR when co-administered with KALETRA.

In a January 2010 review of the PAS, it was noted that there were inconsistencies between the statin labels and the protease inhibitor labels regarding recommendations for co-administration of these products. It was therefore determined that the Office of Clinical Pharmacology (OCP) would review the relevant data on DDIs between statins and HIV and HCV protease inhibitors.

On August 3, 2011 OCP completed its review of the cross labeling initiative for drug interaction updates between protease inhibitors and statins. DMFP was requested to make changes to the atorvastatin and pravastatin labels to provide the results of DDI studies conducted with certain protease inhibitors, and in the case of atorvastatin, to provide dose caps where appropriate, based on the results of the following DDI studies:

- Tipranavir/ritonavir increases atorvastatin AUC and C_{max} 9.4-fold and 8.6-fold, respectively. Because clinical data demonstrating an increased risk of myopathy or rhabdomyolysis with co-administration are lacking, a contraindication was not supported and “Avoid atorvastatin” was recommended for labeling.
- Telaprevir increases atorvastatin AUC and C_{max} 7.88-fold and 10.6-fold, respectively. Because clinical data demonstrating an increased risk of myopathy or rhabdomyolysis with co-administration are lacking, a contraindication was not supported and “Avoid atorvastatin” was recommended for labeling.
- Darunavir/ritonavir increases atorvastatin AUC and C_{max} 3.4-fold and 2.25-fold, respectively. A dose cap of atorvastatin 20 mg was recommended for labeling.
- Fosamprenavir increases atorvastatin AUC and C_{max} 2.3-fold and 4.04-fold, respectively. A dose cap of atorvastatin 20 mg was recommended for labeling.
Based on OCP’s recommendation, DMEP requested the following changes to the atorvastatin and pravastatin labels:

**Atorvastatin:**

Under HIGHLIGHTS OF PRESCRIBING INFORMATION, DRUG INTERACTIONS, Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)</td>
<td>Do not exceed 10 mg atorvastatin daily. Avoid atorvastatin.</td>
</tr>
<tr>
<td>HIV protease inhibitor (lopinavir plus ritonavir)</td>
<td>Use with caution and lowest dose necessary.</td>
</tr>
<tr>
<td>Clarithromycin, itraconazole, HIV protease inhibitors (ritonavir plus saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td>Caution when exceeding doses &gt;20mg atorvastatin daily. The lowest dose necessary should be used. Do not exceed 20 mg atorvastatin daily.</td>
</tr>
<tr>
<td>HIV protease inhibitor (nelfinavir)</td>
<td>Do not exceed 40 mg atorvastatin daily.</td>
</tr>
</tbody>
</table>

Under DOSAGE AND ADMINISTRATION:

**2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors a Combination of Ritonavir plus Saquinavir or Lopinavir plus Ritonavir**

In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the Hepatitis C protease inhibitor (telaprevir), therapy should be limited to with LIPITOR 10 mg once daily should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary employed. In patients with HIV taking clarithromycin, itraconazole, or in patients with HIV taking a combination of ritonavir plus saquinavir plus ritonavir, or lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir for doses of therapy with LIPITOR should be limited to exceeding 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed. In patients with HIV taking nelfinavir, therapy with LIPITOR should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed.

Under 5 WARNINGS AND PRECAUTIONS, 5.1 Skeletal Muscle:
The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibrac acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including ritonavir plus saquinavir plus ritonavir, or lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibrac acid derivatives, erythromycin, clarithromycin, a combination of ritonavir plus saquinavir plus ritonavir, or lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug.

Under Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis:

### Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)</td>
<td>Do not exceed 10 mg atorvastatin daily</td>
</tr>
<tr>
<td>HIV protease inhibitor (ritonavir plus ritonavir)</td>
<td>Avoid atorvastatin</td>
</tr>
<tr>
<td>HIV protease inhibitor (lopinavir plus ritonavir)</td>
<td>Use with caution and lowest dose necessary</td>
</tr>
<tr>
<td>Clarithromycin, itraconazole, HIV protease inhibitors (ritonavir plus saquinavir plus ritonavir, or lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
<td>Caution when exceeding doses &gt; 20 mg atorvastatin daily. The lowest dose necessary should be used.</td>
</tr>
<tr>
<td>HIV protease inhibitor (nelfinavir)</td>
<td>Do not exceed 40 mg atorvastatin daily</td>
</tr>
</tbody>
</table>

*Use with caution and with the lowest dose necessary

Under **DRUG INTERACTIONS, Combination of Protease Inhibitors, 7.1 Strong Inhibitors of CYP 3A4:**

**Combination of Protease Inhibitors:** Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with several combinations of HIV protease inhibitors, as well as with the Hepatitis C protease inhibitor telaprevir, ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitors tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of LIPITOR should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the
A dose of LIPITOR should not exceed 20 mg and should be used with caution. Caution should be used when the LIPITOR dose exceeds 20 mg.

Under 12 CLINICAL PHARMACOLOGY, 12.3 Pharmacokinetics, TABLE 3. Effect of Coadministered Drugs on the Pharmacokinetics of Atorvastatin:

<table>
<thead>
<tr>
<th>Co-administered drug and dosing regimen</th>
<th>Atorvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose (mg)</td>
</tr>
<tr>
<td>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
<td>10 mg, SD</td>
</tr>
<tr>
<td>Nelfinavir 1250 mg BID, 14 days</td>
<td>10 mg QD for 28 days</td>
</tr>
<tr>
<td>Fosamprenavir 1400 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days</td>
<td>10 mg QD for 4 days</td>
</tr>
<tr>
<td>Telaprevir 750 mg q8h, 10 days</td>
<td>20 mg, SD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-administered drug and dosing regimen</th>
<th>Atorvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose (mg)</td>
</tr>
<tr>
<td>* Ritonavir/Saquinavir 400 mg BID/saquinavir/ritonavir 400 mg BID, 15 days</td>
<td>40 mg QD for 4 days</td>
</tr>
</tbody>
</table>

*The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore caution should be applied and the lowest dose necessary should be used.

Under 12 CLINICAL PHARMACOLOGY, 12.3 Pharmacokinetics, TABLE 4. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs:
Pravastatin:

Under 12 CLINICAL PHARMACOLOGY, 12.2 Pharmacokinetics, Table 3: Effect of Coadministered Drugs on the Pharmacokinetics of Pravastatin:

<table>
<thead>
<tr>
<th>Coadministered Drug and Dosing Regimen</th>
<th>Pravastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Drug/Dose (mg)</td>
</tr>
<tr>
<td>Darunavir 600 mg BID/Ritonavir 100 mg BID for 7 days</td>
<td>40 mg single dose</td>
</tr>
<tr>
<td>Kaletra 400 mg/100 mg BID for 14 days</td>
<td>20 mg OD for 4 days</td>
</tr>
</tbody>
</table>

Under 12 CLINICAL PHARMACOLOGY, 12.2 Pharmacokinetics, Table 4: Effect of Pravastatin on the Pharmacokinetics of Coadministered Drugs

<table>
<thead>
<tr>
<th>Pravastatin Dosing Regimen</th>
<th>Name and Dose</th>
<th>Change in AUC</th>
<th>Change in C&lt;sub&gt;max&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mg OD for 4 days</td>
<td>Kaletra 400 mg/100 mg BID for 14 days</td>
<td>No change</td>
<td>No change</td>
</tr>
</tbody>
</table>

A December 6, 2011 OCP review of DDI’s with lovastatin noted that available data support a contraindication with strong CYP3A4 inhibitors, such as the HIV protease inhibitors. The data were summarized as follows:

- According to the Guidance for Industry Drug Interaction Studies, lovastatin is listed as one of the sensitive in vivo CYP3A4 substrates. Therefore, strong CYP3A4 inhibitors are predicted to significantly increase lovastatin exposure because lovastatin is extensively metabolized by CYP3A4 isozyme.
- Literature survey indicates that itraconazole increases lovastatin exposure up to 15- to 20-fold and the drug interaction seems to result in rhabdomyolysis. Itraconazole is the representative strong CYP3A4 inhibitor and therefore, the effect of itraconazole on lovastatin exposure can be extrapolated to other strong CYP3A4 inhibitors listed in the Guidance as well as the FDA website.
• *Strong CYP3A4 inhibitors are contraindicated for simvastatin because of the significant drug interaction and its potential for the increased risk on the rhabdomyolysis. Physicochemical and pharmacokinetic properties of lovastatin are comparable with those of simvastatin. Meanwhile, itraconazole increased the exposure of lovastatin (up to 20-fold) more than that of simvastatin (up to 13-fold), and it indicates that strong CYP3A4 inhibitor can cause greater lovastatin exposure increase compared to that of simvastatin. Therefore, it seems reasonable to extrapolate the effect of strong CYP3A4 inhibitors on simvastatin to that on lovastatin.*

Therefore, concomitant use of lovastatin with HIV protease inhibitors, as well as the HCV protease inhibitors boceprevir and telaprevir, will be contraindicated.

**Lovastatin:**

Under **CONTRAINDICATIONS:**

Concomitant administration with strong CYP3A4 inhibitors, e.g., itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone)

Under **WARNINGS, Myopathy/Rhabdomyolysis, Strong inhibitors of CYP3A4:**

Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a strong inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin. Certain drugs which inhibit this metabolic pathway can raise the plasma levels of lovastatin and may increase the risk of myopathy. These include itraconazole, ketoconazole, and posaconazole, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, or the antidepressant nefazodone. Combination of these drugs with lovastatin is contraindicated.

Under **WARNINGS, Myopathy/Rhabdomyolysis, Table VII: Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis:**

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itraconazole</td>
<td>Avoid. Contraindicated with lovastatin</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td></td>
</tr>
<tr>
<td>Posaconazole</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td></td>
</tr>
<tr>
<td>Telithromycin</td>
<td></td>
</tr>
<tr>
<td>HIV protease inhibitors</td>
<td></td>
</tr>
<tr>
<td>Boceprevir</td>
<td></td>
</tr>
<tr>
<td>Telaprevir</td>
<td></td>
</tr>
<tr>
<td>Nefazodone</td>
<td></td>
</tr>
</tbody>
</table>

Under **PRECAUTIONS, Drug Interactions, CYP3A4 Interactions:**
Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, clarithromycin, telithromycin, HIV protease inhibitors, bocprevir, telaprevir, nefazodone), and erythromycin, and large quantities of grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin.

- Itraconazole
- Ketoconazole
- Erythromycin
- Clarithromycin
- Telithromycin
- HIV protease inhibitors
- Nefazodone
- Large quantities of grapefruit juice (>1 quart daily)

4. Increases in HbA1c and fasting plasma glucose – TSI #891

On April 8, 2010 TSI #891 was opened to evaluate the effect of statins on increases in HbA1c and fasting plasma glucose. This was based on findings from the JUPITER trial, which reported a 27% increase in investigator-reported diabetes mellitus in rosuvastatin-exposed subjects compared to placebo-exposed subjects. High-dose atorvastatin had previously been associated with worsening glycemic control in the PROVE-IT TIMI 22 substudy.

Several articles from the published literature were also considered, including:

Culver AL et al. Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative. *Arch Intern Med.* Published online January 9, 2012.

The Sattar meta-analysis, which looked at 13 statin trials with 91,140 participants, reported that “statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity ($I^2=11\%$) between trials.”

The Rajpathak meta-analysis, which looked at 6 statin trials with 57,593 participants, reported a “small increase in diabetes risk” (relative risk [RR] 1.13; 95% CI 1.03-1.23), with “no evidence of heterogeneity across trials”.

The Mills meta-analysis, which looked at 76 randomized clinical trials (RCTs) with 170,255 participants, reported that 17 RCTs reported on increased risk of development of incident diabetes (Odds ratio [OR] 1.09; 95% CI 1.02-1.17, $p=0.001$, $I^2=11\%$).

Culver et al looked at postmenopausal women participating in the Women’s Health Initiative (WHI) to investigate whether the incidence of new-onset diabetes mellitus is associated with statin use. The study involved 153,840 women. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83); the multivariate-adjusted HR was 1.48; 95% CI, 1.38-1.59. The association was observed for all types of statin medications.

At the time of approval of the JUPITER supplement, the following labeling was required for CRESTOR:

5.5 Endocrine Effects

Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including CRESTOR.

The data for an effect of statins on incident diabetes, and increases in HbA1c and/or fasting plasma glucose seem to indicate a class effect; however, given the limitations of epidemiological data, and the findings from the West of Scotland Coronary Prevention Study (WOSCOPS) clinical trial, which suggested that pravastatin may decrease the incidence of diabetes by 30%, the division did not seek a labeling change for pravastatin.

Therefore, based on clinical trial data, epidemiological data, and the published literature, the following labeling change was requested for all statins except pravastatin:

5.X Endocrine Function:

Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including <<STATIN>>.
5. **Drug-drug interaction with ranolazine – TSI #988**

TSI #988 was opened by the Division of Cardiovascular and Renal Products (DCRP) in July 2010 when during routine data monitoring of the AERS database for cases of ranolazine and torsades de pointes, a signal was identified for rhabdomyolysis in patients receiving ranolazine and statins.

Nine cases of drug interaction were related to concomitant use of ranolazine and a statin. Of those nine cases, seven (all male) involved the statin associated adverse events of rhabdomyolysis (6) and myalgia (1). Four of those six patients were stable on long-term statin therapy prior to the initiation of ranolazine. Most cases involved the use of simvastatin.

According to the OCP review:

*Ranolazine and SV are both cleared via CYP3A metabolism. Hence, concomitant administration of the two may lead to pharmacokinetic DDI. Administration of ranolazine (1000 mg twice daily) with SV (80 mg once daily) resulted in a ~2-fold increase in Cmax and ~1.5-fold increase in AUC of SV and SVA, at steady state. Increased systemic exposure to SV and SVA has been associated with increased risk of myopathy and rhabdomyolysis. The 80 mg dose of SV has been shown to be associated with increased incidence of myopathy and rhabdomyolysis. In addition, there is little gain in effectiveness of the 80 mg over 40 mg dose. The DMEP regulatory briefing held on 6/4/2010 suggested progressive removal of 80 mg dose of simvastatin from the market, leaving 40 mg as the highest available dose. Therefore, given the 2-fold increase in systemic exposure expected on concomitant administration of ranolazine and SV, limiting the dose of SV to 20 mg will avoid exposures similar or greater to that observed with 80 mg.*

*In addition, for other statins which are primarily metabolized by CYP3A (e.g., lovastatin and atorvastatin), concomitant medications which are CYP3A inhibitors are expected to elevate statin exposure, and risk of myopathy. However, at present, definitive data (such as available with simvastatin) is not available for other statins, in order to recommend dose-adjustments.*

On June 8, 2011, in conjunction with the approval of new dosing restrictions with the 80 mg dose of simvastatin, DMEP approved a dose cap of simvastatin 20 mg when simvastatin is coadministered with ranolazine.

In addition, the current ranolazine label recommends a dose adjustment of sensitive CYP3A4 substrates such as lovastatin based on the 2-fold simvastatin exposure increase by ranolazine.
Based on the information above, the following recommendations for labeling changes were made:

Mevacor:

Under **WARNINGS, Myopathy/Rhabdomyolysis:**

*Ranolazine:* The risk of myopathy, including rhabdomyolysis, may be increased by concomitant administration of ranolazine. Dose adjustment of lovastatin may be considered during co-administration.

Under **PRECAUTIONS, Other Drug Interactions:**

*Ranolazine:* The risk of myopathy, including rhabdomyolysis, may be increased by concomitant administration of ranolaze.

Altoprev:

Advicor:

6. **Myopathy with concomitant administration with colchicine**

In June 2010, a Regulatory Briefing was conducted to discuss the increased risk of myopathy, including rhabdomyolysis, associated with the use of simvastatin 80
mg, based on DMEP’s review of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) clinical trial. In preparation for the briefing, OSE noted an interaction between statins and colchicine resulting in an increased risk of myopathy. Colchicine, a substrate of P-glycoprotein and CYP3A4, carried the following information in its label:

5.4 Neuromuscular Toxicity
Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, gemfibrozil, fenofibrate, fenofibric acid, or benzafibrate (themselves associated with myotoxicity) or cyclosporine may potentiate the development of myopathy. Once colchicine is stopped, the symptoms generally resolve within 1 week to several months.

This was based on reports from the literature as summarized in the table below, and adapted from a 2008 OCP review of NDA 22-352 (Colstat [colchicine tablets]).

<table>
<thead>
<tr>
<th>Lipid Lowering Agents</th>
<th>Simvastatin: Baker et al. (2004); Hsu et al. (2002)</th>
<th>Both are CYP3A4 and P-gp substrates; P-gp inhibition by simvastatin</th>
<th>Acute myopathy or rhabdomyolysis (could be attributed to either drug)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Fluvastatin: Atasoy et al. (2005)</td>
<td>Synergistic myotoxicity via PK &amp; PD mechanism; fluvastatin is not a P-gp inhibitor</td>
<td></td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Pravastatin: Alavli et al. (2005)</td>
<td>Synergistic myotoxicity via PK &amp; PD mechanism; pravastatin is not a P-gp inhibitor</td>
<td></td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitors</td>
<td>Atorvastatin: Tu &amp; Fan et al. (2006)</td>
<td>Both are CYP3A4 substrates; P-gp inhibition by atorvastatin</td>
<td></td>
</tr>
</tbody>
</table>

On June 8, 2011, the following changes were approved for the simvastatin-containing drugs:

5 WARNINGS AND PRECAUTIONS
5.1 Myopathy/Rhabdomyolysis
Cases of myopathy, including rhabdomyolysis, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine.

7 DRUG INTERACTIONS
7.7 Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with simvastatin coadministered with colchicine, and caution should be exercised when prescribing simvastatin with colchicine.
In order to harmonize and update the appropriate statin labels, similar labeling changes were requested for atorvastatin, pravastatin, and fluvastatin. Furthermore, because of physicochemical and pharmacokinetic similarities between lovastatin and simvastatin, similar labeling changes were requested for lovastatin.

7. Myopathy with concomitant administration with fibrates

A National Institutes of Health (NIH) funded trial, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial, was reviewed by DMEP and discussed at an Advisory Committee meeting on May 19, 2011. ACCORD-Lipid evaluated the occurrence of major adverse cardiovascular events (MACE), a composite of nonfatal heart attack, nonfatal stroke, and cardiovascular death in patients receiving simvastatin plus fenofibrate, compared to simvastatin alone. The trial found that there was no difference in cardiovascular outcomes between the two groups (Hazard Ratio = 0.92; 95% Confidence Interval: 0.79-1.08; p=0.32).

This was the second failed cardiovascular outcome trial for fenofibrate. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (Hazard Ratio = 0.89; 95% Confidence Interval: 0.75-1.05; p=0.04) versus placebo.

The absence to date of proven cardiovascular benefit with fenofibrates must be viewed in the context of observational data showing an increase in the risk of myopathy with fenofibrates, especially when co-administered with a statin. In 2011, OSE conducted a review of observational data on rhabdomyolysis with fenofibrates and gemfibrozil in combination with statins. Their review looked at 3 studies:


According to the OSE review, the best available evidence suggests that fenofibrate-statin combination is associated with an increased hazard rate for rhabdomyolysis (HR, 3.26, 95% CI, 1.21-8.80) relative to statin monotherapy. There also appears to be a differential risk associated with the gemfibrozil-statin combination therapy versus the fenofibrate-statin combination therapy, with a
numerically higher rate of rhabdomyolysis observed with gemfibrozil-statin combination therapy (HR, 11.93, 95% CI, 3.96-35.93) compared to statin monotherapy.

Most statin labels contain language in the FPI (Warnings and Precautions and Drug Interactions sections) regarding the increased risk of myopathy, including rhabdomyolysis, when statins and fibrates are co-administered. In order to highlight this increased risk, as well as to note the differential risk between gemfibrozil-statin combination therapy and fenofibrate-statin combination therapy, all sponsors of statin drugs with labels in the PLR format (i.e., all except the lovastatin products) were requested to add the following information to the Highlights page. The following language was also provided in the Drug Interactions section of the PI’s, depending on the level of risk determined for each statin product:

---DRUG INTERACTIONS---

Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with <<STATIN>>.

7.X Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone
- Gemfibrozil: <<Contraindicated or Avoid>> with <<STATIN>>
- Other fibrates: Caution should be used when prescribing with <<STATIN>>

7.X Gemfibrozil
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of <<STATIN>> with gemfibrozil should be avoided.

7.X Other Fibrates
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, <<STATIN>> should be administered with caution when used concomitantly with other fibrates.

8. Myopathy with concomitant administration with lipid-modifying doses of niacin

In March 2010, DMEP approved a labeling revision for simvastatin based on interim results from an ongoing clinical trial - the Heart Protection Study 2 (HPS2) – Treatment of HDL to Reduce the Incidence of Vascular Events (THRIVE), a cardiovascular outcome trial being conducted in 20,000 patients with vascular disease from the UK, China and Scandinavia to investigate whether combining niacin with a new drug (laropiprant) that minimizes niacin’s flushing effect can reduce the risk of serious heart attacks and strokes among people already taking treatment to lower their LDL-cholesterol. The interim HPS2 – THRIVE results showed that the incidence of myopathy was higher in patients of
Chinese descent (0.43%) compared with patients not of Chinese descent (0.03%) taking 40 mg simvastatin plus cholesterol-modifying doses (≥1 g/day) of a niacin-containing product. The exact mechanism of this drug interaction is not fully understood.

Drug-drug interaction studies report an increase in simvastatin exposure of 41-64% with co-administration of simvastatin and ER niacin. According to OCP, the cause of the observed changes in exposure of simvastatin due to ER niacin is not well established as this is not due to changes in the known pathways (e.g., via CYP3A4 or OATP1B1). Furthermore, a PK study of simvastatin in Chinese subjects showed no significant differences in Chinese and non-Asian subjects in simvastatin C\text{max} and AUC\text{0–last}, and simvastatin acid AUC\text{0–last} or C\text{max}.

The OCP Genomics Group further noted that the SLCO1B1 genotype that has been associated with statin-induced myopathy, is less prevalent in Asian populations than European populations and, therefore, does not seem to explain the higher myopathy risk rates among Chinese subjects in HPS2-THRIVE.

So, it remains unclear if this increased risk of myopathy with statin and niacin co-administration is unique to Chinese subjects, or applies to other Asians and non-Asians as well.

Furthermore, in the AIM-HIGH study, which compared ER-niacin with simvastatin to simvastatin alone in reducing the residual cardiovascular risk in patients with established cardiovascular disease, “there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels”.

The lack of clear benefit in conjunction with uncertainty as to the nature of the increased risk of myopathy in patients treated with niacin plus a statin led FDA to believe that this risk needed to be highlighted in statin labeling.

The labeling approved for simvastatin in March 2010 noted that patients of Chinese descent should not receive simvastatin 80 mg with cholesterol-modifying doses of niacin-containing products.

In June 2011, in conjunction with labeling revisions required based on the Agency’s review of the SEARCH trial, this language was modified to note that “caution should be used when treating Chinese patients with simvastatin doses exceeding 20 mg/day coadministered with lipid-modifying doses of niacin-containing products.”

Most statin labels contain information in the FPI (Warnings and Precautions and Drug Interactions sections) noting that “The risk of skeletal muscle effects may be enhanced when <<STATIN>> is used in combination with niacin; a reduction in
Dosage should be considered in this setting.” All sponsors of statin drugs with labels in the PLR format were requested to modify the HIGHLIGHTS page, with corresponding changes to the FPI if indicated, as follows:

---DRUG INTERACTIONS---

Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with <<STATIN>>.

7.X Niacin
The risk of skeletal muscle effects may be enhanced when <<STATIN>> is used in combination with lipid-modifying doses (≥1 g/day) of niacin; a reduction in <<STATIN>> dosage should be considered in this setting.

9. Update to lovastatin drug-drug interactions and dose caps

Subsequent to the June 2011 labeling revisions to the simvastatin-containing products which were largely based on the SEARCH clinical trial data and the increased risk of myopathy associated with the 80 mg dose of simvastatin, a review of drug-drug interactions with lovastatin was conducted. The physicochemical and pharmacokinetic properties of lovastatin are comparable with those of simvastatin. Lovastatin is a sensitive in vivo CYP3A4 substrate; therefore, strong CYP3A4 inhibitors are predicted to significantly increase lovastatin exposure. According to OCP:

*Itraconazole increased the exposure of lovastatin (up to 20-fold) more than that of simvastatin (up to 13-fold), and it indicates that strong CYP3A4 inhibitor can cause greater lovastatin exposure increase compared to that of simvastatin. Therefore, it seems reasonable to extrapolate the effect of strong CYP3A4 inhibitors on simvastatin to that on lovastatin.*

Based on available studies from the literature, as well as extrapolation from simvastatin data, the following changes to the lovastatin label were recommended:

Under **CONTRAINDICATIONS:**

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin and nefazodone).

Under **WARNINGS, Myopathy/Rhabdomyolysis, Strong Potent inhibitors of CYP3A4:**

Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of
CYP3A4, elevated plasma levels of HMG CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin. Certain drugs which inhibit this metabolic pathway can raise the plasma levels of lovastatin and may increase the risk of myopathy. These include itraconazole, ketoconazole, and posaconazole, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, or the antidepressant nefazodone. Combination of these drugs with lovastatin is contraindicated.

The use of lovastatin concomitantly with the potent CYP3A4 inhibitors itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, or large quantities of grapefruit juice (>1 quart daily) should be avoided. Concomitant use of other medicines labeled as having a potent strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk. If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with lovastatin should be suspended during the course of treatment.

Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentration of lovastatin. It is recommended that dose adjustment of lovastatin be considered during coadministration. Increased lovastatin concentration in plasma has been associated with an increased risk of myopathy/rhabdomyolysis.

Under WARNINGS, Myopathy/Rhabdomyolysis:

- **Gemfibrozil, particularly with higher doses of lovastatin:** The dose of lovastatin should not exceed 20 mg daily in patients receiving concomitant medication with gemfibrozil. The combined use ofLovastatin with gemfibrozil should be avoided, unless the benefits are likely to outweigh the increased risks of this drug combination.

- **Other lipid-lowering drugs (other fibrates or ≥1 g/day of niacin):** The dose of lovastatin should not exceed 20 mg daily in patients receiving concomitant medication with other fibrates or ≥1 g/day of niacin. Caution should be used when prescribing other fibrates or lipid-lowering doses (≥1 g/day) of niacin with lovastatin, as these agents can cause myopathy when given alone. The benefit of further alterations in lipid levels by the combined use of Lovastatin with other fibrates or niacin should be carefully weighed against the potential risks of these combinations.

- **Cyclosporine:** The use ofLovastatin with cyclosporine should be avoided.

- **Cyclosporine or dDanazol, diltiazem or verapamil with higher doses of Lovastatin:** The dose ofLovastatin should not exceed 20 mg daily in patients receiving concomitant medication with cyclosporine or danazol, diltiazem, or verapamil. The benefits of the use ofLovastatin in patients receiving cyclosporine or danazol, diltiazem, or verapamil should be carefully weighed against the risks of these combinations.

- **Amiodarone or verapamil:** The dose ofLovastatin should not exceed 40 mg daily in patients receiving concomitant medication with amiodarone or verapamil. The combined use of Lovastatin at doses higher than 40 mg daily with amiodarone or verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk of myopathy. The risk of myopathy/rhabdomyolysis is
increased when either amiodarone or verapamil is used concomitantly with higher doses of a closely related member of the HMG-CoA reductase inhibitor class.

Under **WARNINGS, Myopathy/Rhabdomyolysis:**

**Cyclosporine:** The use of lovastatin with cyclosporine should be avoided.

**Amiodarone or verapamil:** The dose of lovastatin should not exceed 40 mg daily in patients receiving concomitant medication with amiodarone or verapamil. The combined use of lovastatin at doses higher than 40 mg daily with amiodarone or verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk of myopathy. The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with higher doses of a closely related member of the HMG-CoA reductase inhibitor class.

**Cyclosporine, dDanazol, diltiazem or verapamil** with higher doses of lovastatin: The dose of lovastatin should not exceed 20 mg daily in patients receiving concomitant medication with cyclosporine, or danazol, diltiazem, or verapamil. The benefits of the use of lovastatin in patient receiving cyclosporine, or danazol, diltiazem, or verapamil should be carefully weighed against the risks of these combinations.

Under **WARNINGS, Myopathy/Rhabdomyolysis, Table VII: Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis:**

<table>
<thead>
<tr>
<th>Interacting Agents</th>
<th>Prescribing Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoconazole</td>
<td>Avoid Contraindicated with lovastatin</td>
</tr>
<tr>
<td>Itraconazole</td>
<td></td>
</tr>
<tr>
<td>Posaconazole</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td></td>
</tr>
<tr>
<td>Telithromycin</td>
<td></td>
</tr>
<tr>
<td>HIV protease inhibitors</td>
<td></td>
</tr>
<tr>
<td>Boceprevir</td>
<td></td>
</tr>
<tr>
<td>Telaprevir</td>
<td></td>
</tr>
<tr>
<td>Nefazodone</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>Avoid with lovastatin</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>Do not exceed 20 mg lovastatin daily</td>
</tr>
<tr>
<td>Other fibrates</td>
<td></td>
</tr>
<tr>
<td>Lipid lowering doses (≥1 g/day) of nicacin</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
</tr>
<tr>
<td>Danazol</td>
<td>Do not exceed 40 mg lovastatin daily</td>
</tr>
<tr>
<td>Diltiazem</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td></td>
</tr>
<tr>
<td>Grapefruit juice</td>
<td>Avoid large quantities of grapefruit juice (&gt;1 quart daily)</td>
</tr>
</tbody>
</table>

Under **PRECAUTIONS, Drug Interactions, CYP3A4 Interactions:**
Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and erythromycin), and large quantities of grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin.

\[
\text{Itraconazole, Ketoconazole, Erythromycin, Clarithromycin, Telithromycin, HIV protease inhibitors, Nefazodone, Large quantities of grapefruit juice (>1 quart daily)}
\]

*In vitro* studies have demonstrated that voriconazole inhibits the metabolism of lovastatin. Adjustment of the lovastatin dose may be needed to reduce the risk of myopathy, including rhabdomyolysis, if voriconazole must be used concomitantly with lovastatin.

Under **PRECAUTIONS, Other Drug Interactions:**

*Cyclosporine or Danazol:* The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of lovastatin.

*Danazol, Diltiazem, or Verapamil:* The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol, diltiazem, or verapamil particularly with higher doses of lovastatin.

*Amiodarone or Verapamil:* The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class.

Under **PRECAUTIONS, Endocrine Function:**

Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones.

Under **DOSAGE AND ADMINISTRATION:**

**Dosage in Patients taking Cyclosporine, or Danazol, Diltiazem, or Verapamil**

In patients taking cyclosporine, or danazol, diltiazem, or verapamil concomitantly with lovastatin, therapy should begin with 10 mg of lovastatin and should not exceed 20 mg/day.

**Dosage in Patients taking Amiodarone or Verapamil**

In patients taking amiodarone or verapamil concomitantly with MEVACOR, the dose should not exceed 40 mg/day.
Concomitant Lipid-Lowering Therapy

MEVACOR is effective alone or when used concomitantly with bile-acid sequestrants. If MEVACOR is used in combination with gemfibrozil, other fibrates or lipid lowering doses (≥ 1g/day) of niacin, the dose of MEVACOR should not exceed 20 mg/day.

Under CLINICAL PHARMACOLOGY:

<table>
<thead>
<tr>
<th>Dosing of Coadministered Drug or Grapefruit Juice</th>
<th>Dosing of Lovastatin</th>
<th>AUC Ratio* (with / without coadministered drug)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovastatin</td>
<td>Lovastatin acid†</td>
<td></td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>11</td>
<td>600 mg BID for 3 days</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>12</td>
<td>200 mg QD for 4 days</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>10</td>
<td>100 mg QD for 4 days</td>
</tr>
<tr>
<td>Grapefruit Juice (high dose)</td>
<td>10</td>
<td>200 mL of double-strength TID§</td>
</tr>
<tr>
<td>Grapefruit Juice (low dose)</td>
<td>16</td>
<td>8 oz (about 250 mL) of single-strength† for 4 days</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>16</td>
<td>Not describedβ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosing of Lovastatin</th>
<th>AUC Ratio* (with / without coadministered drug)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovastatin acid†</td>
<td>No Effect = 1.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of Subjects</th>
<th>Dosing of Coadministered Drug or Grapefruit Juice</th>
<th>Dosing of Lovastatin</th>
<th>AUC Ratio* (with / without coadministered drug)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diltiazem</td>
<td>10</td>
<td>120 mg BID for 14 days</td>
<td>20 mg</td>
</tr>
</tbody>
</table>

* Results based on a chemical assay
† Lovastatin acid refers to the β-hydroxyacid of lovastatin
‡ The mean total AUC of lovastatin without itraconazole phase could not be determined accurately. Results could be representative of strong CYP3A4 inhibitors such as ketoconazole, posaconazole, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone
§ Estimated minimum change
† The effect of amounts of grapefruit juice between those used in these two studies on lovastatin pharmacokinetics has not been studied
§ Double-strength: one can of frozen concentrate diluted with one can of water. Grapefruit juice was administered TID for 2 days, and 200 mL together with single dose lovastatin and 30 and 90 minutes following single dose lovastatin on Day 3
¶ Single-strength: one can of frozen concentrate diluted with 3 cans of water. Grapefruit juice was administered with breakfast for 3 days, and lovastatin was administered in the evening on Day 3
β Cyclosporine-treated patients with psoriasis or post kidney or heart transplant patients with stable graft function, transplanted at least 9 months prior to study
³ Cyclosporine

10. Update to simvastatin and lovastatin drug-drug interaction:

In May 2011, the hepatitis C protease inhibitors boceprevir and telaprevir were approved. These protease inhibitors have been characterized as being strong CYP3A4 inhibitors. Because simvastatin is contraindicated with strong CYP3A4 inhibitors, and because the simvastatin label individually lists strong CYP3A4 inhibitors with which simvastatin is contraindicated, these two recently approved protease inhibitors will be added to the list in all simvastatin-containing products (Zocor, Vytorin, and Simcor).

Because of the physicochemical and pharmacokinetic similarities between simvastatin and lovastatin, and consistent with changes being made to the lovastatin labeling which include a new contraindication with strong CYP3A4 inhibitors, the labeling for lovastatin will be modified to add boceprevir and telaprevir to the list of strong CYP3A4 inhibitors with which lovastatin is contraindicated.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMY G EGAN
02/27/2012
APPLICATION NUMBER:
020702Orig1s060

OTHER REVIEW(S)
Division of Metabolism & Endocrine Products

Labeling Review

Application Number: NDA 20702/S-060

Name of Drug: Lipitor (atorvastatin) Tablets

Sponsor: Pfizer

Submission Date: September 30, 2011; Final PI/PPI- February 21, 2012 (email)

Background and Summary:

Lipitor is indicated:
1. as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
2. as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
3. for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
4. to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable.
5. as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
   a. LDL-C remains $\geq 190$ mg/dL or
   b. LDL-C remains $\geq 160$ mg/dL and:
      there is a positive family history of premature cardiovascular disease or
two or more other CVD risk factors are present in the pediatric patient

It is supplied in the tablet dose strengths of 10, 20, 40 and 80 mg.

The last approved Package Insert (PI) was S-056, which provided changes in the format of the Lipitor package and patient package insert in response to the Physician’s Labeling Rule.

This supplement, S-060, provides for revisions to the WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS sections of the Highlights of Prescribing Information section and changes to the DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DRUG INTERACTIONS, CLINICAL PHARMACOLOGY and
PATIENT COUNSELING INFORMATION sections of the Full Prescribing Information sections of the LIPITOR (atorvastatin) package insert, and corresponding revisions to the LIPITOR (atorvastatin) patient package insert.

Review:

A track change version including all labeling changes since the last approved label and a final, clean version of the PI and PPI have been attached to the approval letter.

Conclusion:

The PI (Package Insert Identifier number is LAB-0021-27.0 Revised 02/2012) was reviewed by Dr. Egan and deemed acceptable. Agency will issue an approval letter on this labeling supplement.

The PPI identifier number is LAB-0348-7.0 February 2012.

Reviewed by: M.A. Simoneau, R.Ph., Regulatory Project Manager
(See appended electronic signature page)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARGARET A SIMONEAU
02/28/2012